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INVESTIGATIONS OF THE STRUCTURE-FUNCTION RELATIONSHIP IN
KAINATE RECEPTORS USING FÖRSTER RESONANCE ENERGY TRANSFER
Abstract
Douglas Bryan Litwin, M.S.

Advisory Professor: Vasanthi Jayaraman, Ph.D.

Kainate receptors belong to the family of ion channels known as the ionotropic
glutamate receptors. Ionotropic glutamate receptors mediate the majority of
excitatory synaptic transmission, modulate the release of presynaptic glutamate, and
facilitate dendrite formation. Kainate receptors are unique among the ionotropic
glutamate receptors in being modulated by sodium ions. They have also been
implicated in the development of higher learning and epilepsy. In recent years a
wealth of structural data has become available for the AMPA and NMDA classes;
however, the structural characterization of kainate receptors has been limited. The
work in this dissertation utilizes luminescence resonance energy transfer (LRET) and
single molecule Förster Resonance Energy Transfer (smFRET) in order to
address this gap in the knowledge. We have characterized the structural
arrangement and dynamics of the homomeric (GluKU) receptors and
identified structural changes involved in the functional modulation by ions
and auxiliary proteins. Additionally, we have characterized the arrangement
and dynamics of the heteromeric (GluKU/GluKd). These data will build a
viii

foundation for the full biophysical characterization of kainate receptors; and
contribute to the development of subunit-specific modulatory compounds to
be used for disease therapies, and for more detailed characterization of brain
function at the molecular level.
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Chapter 1: Introduction

Cell signaling with the speed required for the complex physiology found in
vertebrates is made possible through the modulation of an electrical voltage gradient
within neurons. These signals are conducted at high speed down neuronal axons
where they are sent to downstream neurons at junctions called synapses. At the
synapse, the signal can be electrically relayed between neurons or converted to a
chemical signal which can then generate an electrical signal in the downstream
neuron, known as synaptic transmission.
The voltage gradient utilized for synaptic transmission is created and
maintained by numerous classes of ion pumps and channels. These channels and
pumps modulate the voltage gradient by displacing ions in (K+) and out (Na+ and Cl-)
of the cell which creates net positive charge outside of the neuron. Synaptic
transmission can induce both excitatory and inhibitory signals in the receiving
neuron. Excitatory reception induces depolarization by allowing Na+ back into the cell
and inhibitory signals induce hyperpolarization by allowing Cl- to reenter the
postsynaptic membrane or K+ out of the cell. Ionotropic glutamate receptors (iGluRs)
are the primary carriers of excitatory signaling and Gamma-aminobutyric acid (GABA)
receptors are the primary carriers of inhibitory signaling in the central nervous system
(CNS).
Kainate receptors are members of the iGluR family of ion channels which are
typically permeable to Na+, K+ and sometimes CaU+. The iGluR family consists of the αamino-\-hydroxy-d-methyl-[-isoxazole propionate (AMPA), kainate, and N-methyl-D1

aspartate (NMDA) receptor subtypes. All subtypes assemble as tetrameric proteins
composed of a combination of subtype-specific subunits; GluAW-[ for AMPA, GluKW-d
for kainate, and GluNW-\ for NMDA (W, U). Prior studies have revealed that iGluRs
function in the reception of excitatory synaptic signaling, the facilitation and
inhibition of presynaptic GABA and glutamate release, and neuronal dendrite
formation and growth (U-[).
Although the exact mechanisms behind cognition, learning and memory are
not fully resolved, it is well established that iGluRs are critical in these processes. Not
surprisingly, iGluRs have been implicated in various disease states including
neurological developmental disorders, schizophrenia, autism, and epilepsy (d, ]). This
makes iGluRs of particular interest for the development of novel modulatory
compounds for therapeutic applications. These novel compounds would not only be of
interest to physicians treating patients affected by neurological disorders but would
also make it possible for scientists to more accurately study the specific roles of iGluRs
in the brain. However, attempts to target iGluRs for the therapeutic intervention of
diseases has yielded little progress due to the ubiquitous integration of iGluR function
into basal physiological activity. Targeting AMPA, NMDA, and kainate receptors
individually has consistently been limited by off-target effects resulting from overlap
in their pharmacological profiles. The solution to this issue is to target not only iGluR
subtypes but also the different subunit combinations with which subtypes assemble in
the brain.
Since the first pharmacological characterization of iGluRs, numerous groups
have attempted to identify novel iGluR-modulating compounds (f-Wd). However,
2

developing methods capable of high throughput screening potential compounds for
iGluR modulating activities has been a difficult and time-consuming process. These
investigations have yielded a number of compounds with high specificity for iGluR
subtypes, particularly the AMPA and NMDA subtypes, but the majority of these
compounds have been limited to use in the laboratory. The most promising clinicallyrelevant compounds produced have been NMDA antagonists including ketamine,
memantine, methadone, and dextromethorphan.
While these compounds have proven useful in certain neuropathies, their
applications, as with other AMPA and kainate candidate compounds, have been
limited by unwanted and/or toxic side effects (W]-UV). Therefore, given the success of
structure-based drug design with other proteins including the NMDA receptor (UW-U\),
it seems likely that a thorough understanding of the structural conformations and
solvent-accessible topological chemistries unique to each iGluR subtype will be
required to allow for the design of compounds with higher subtype specificity.
Beginning in the early UVVV’s, researchers began resolving the first structural
models of iGluRs. These studies initially resolved crystal structures of isolated
extracellular domains and eventually culminated with high-resolution crystallography
and cryo-EM models of the full-length proteins (U[-\U). The vast majority of the fulllength models available are of AMPA and NMDA receptors with limited structural
data produced for full-length kainate receptors. These structural models have
revolutionized our understanding of the mechanics underlying iGluR function.
However, uncertainties resulting from the static conditions required for X-ray and
electron-based imaging, and functional data produced that conflicts with structure3

based interpretations of the dynamic requirements for receptor gating have left many
unanswered questions concerning the structural characteristics unique to each
subtype (\\, \[).
To address this gap in knowledge, the work presented in this dissertation aims
to examine the dynamic movements and conformational changes involved in fulllength kainate receptor gating and the unique aspects of their functional
characteristics, including modulation by ions and auxiliary proteins. The FRET data
presented herein seeks to build on prior knowledge available for the structurefunction relationship in kainate receptors and resolve the structural and dynamic
properties that give rise to the unique structure-function characteristics of kainate
receptors.

4

Chapter 2: Kainate Receptor Function and Physiology

Kainic acid (kainate) is a naturally occurring marine toxin produced by certain
species of seaweed. It was historically known that ingestion of kainate induced severe
excitotoxic and convulsive responses in mice and humans. In WXf[ the first study
identifying the excitatory effect of kainate on crayfish muscles was published (\d).
This study showed that kainate induces excitatory responses in neuromuscular
junctions that are nearly identical to those induced by glutamate. It was later
discovered that kainate was acting preferentially on a subtype of glutamate receptor
that became known as kainate receptors.
Shortly after the first studies on kainate, it was shown that exposure to alphaAmino-\-hydroxy-d-methyl-[-isoxazolepropionic acid (AMPA) produced similar
excitotoxic effects in animals (\]). The similar physiological responses resulting from
kainate and AMPA exposure were quickly explained by significant overlap in their
pharmacological profiles (\f) and this overlap was not found with NMDA class
receptors. While the pharmacological similarities between the kainate and AMPA
receptor have made it difficult to resolve the functional characteristics of each
subtype, distinct and unique functional properties have since been identified for
kainate receptors.
It was subsequently shown that iGluRs exist in three functional states: resting,
active and desensitized. Under resting conditions, the receptor is not bound to agonist
and non-conductive. Under active conditions the receptor is agonist-bound and
conducts ions. Under desensitized conditions the receptor is agonist-bound and non5

conductive. The transitions between these states are described by their activation,
deactivation, and desensitization and resensitization kinetics. Activation kinetics
describe the receptors speed of response to agonist. Deactivation kinetics describe the
speed of channel inactivation under sub-saturating agonist conditions.
Desensitization kinetics describe the speed of channel inactivation under saturating
agonist conditions, and resensitization kinetics describe the speed at which the
receptors recover from the non-active state.
On the post-synaptic neuron, kainate and AMPA receptors function to mediate
the fast component of excitatory synaptic transmission. Both kainate and AMPA
receptors carry the initial response to presynaptically released glutamate; however,
kainate receptors typically have a slower activation and prolonged deactivation
kinetics (U). Additionally, kainate receptors show longer rates of recovery from the
inactive state. In contrast, NMDA receptors are characterized by a delayed response
induced by Mg+ blocking the ion channel pore, which requires a prior depolarization
at the post-synaptic membrane to release (U). These data are not surprising given the
high primary sequence homology between AMPA and KARs which is significantly
lower between the two and the NMDAR.
Studies characterizing the in vivo electrophysiological functions of KARs have
been limited due to the lack of specific pharmacological compounds; however, the
development of the U,\-benzodiazepine class of antagonists, which are more selective
for AMPARs than KARs, made it possible to characterize the synaptic functions of
KARs for the first time. Using these antagonists it was shown that KARs mediate
excitatory synaptic transmission in the CAW region of the hippocampus (\Y).
6

Subsequent studies identified their involvement in excitatory synaptic transmission at
other hippocampal synapses (\X-[W), in the retina ([U), spinal cord ([\), amygdala
([[), and cortex ([d).
The most interesting finding resulting from these initial studies was that high
agonist concentration inhibited presynaptic glutamate release (\Y). These results
hinted that KARs could be localized and functioning pre-synaptically, which was later
confirmed by studies showing that KARs are able to inhibit presynaptic glutamate
release in the neocortex ([]) and cerebellum ([f). The presynaptic roles of KARs were
expanded when it was shown that KARs can regulate the release of the inhibitory
neurotransmitter GABA at hippocampal synapses ([Y, [X). Additional studies showed
that kainate receptors are able to facilitate and inhibit GABA release through
metabotropic signaling mechanisms ([X, dV). These presynaptic roles of kainate
receptors are still not fully resolved yet highlight their potential of regulating
excitatory networks in specific regions of the brain.
After being cloned and characterized in greater molecular detail, it was shown
that KARs are tetrameric assemblies of subunits GluKW-d. Each subunit was shown to
be modular with an amino-terminal domain (ATD), agonist-binding domain (ABD), a
transmembrane domain (TMD) and a Carboxyl-terminal domain (CTD). While these
studies confirmed that all iGluR have similar architecture, the structure/function
relationship of each class remained to be characterized.
KARs function to produce excitatory post-synaptic currents (EPSCs) with
different properties through the combination of different subunits in homomeric and
heteromeric receptors. GluKW-\ function as homomeric or heteromeric assemblies,
7

while GluK[-d require co-expression with either GluKW or GluKU to form functional
channels (W). The homomeric GluKU receptor has been studied in the greatest detail,
however, the GluKU/GluKd heteromeric receptors are the most commonly expressed
KAR in the brain. Interestingly, KAR subunits able to form homomeric channels have
a significantly lower affinity for glutamate than those that cannot. This has led to
GluKW-\ being termed low affinity and GluK[-d being termed high affinity KARs.
Different functional properties can also be obtained from mRNA editing,
alternative splicing, and post-translational modifications of the receptors. mRNA
editing at sites within the transmembrane helices of GluKW and GluKU can result in
changes of ion permeability (dW). Alternative splicing within the GluKW and GluKU Cterminal results in endoplasmic reticulum retention of the receptors (dU).
Phosphorylation of the C-terminal of GluKW results in receptor internalization, while
phosphorylation of the GluKU C-terminal results in potentiation (U, d\-dd). It is also
known that SUMOylation of the KAR C-terminal domain can reversibly induce
receptor internalization.
While the kainate-mediated EPSCs first found in the CAW region were small in
amplitude, it was later shown that KARs produce significant currents in the CA\
region of the hippocampus and in the cortex ([d, d]). Biochemical, pharmacological,
and genetic methods have provided some insight into the composition of the KAR
subunits within these regions. The GluKW-specific agonist U-Amino-\-(\-hydroxy-dtert-butylisoxazol-[-yl) propionic acid (ATPA) revealed that the GluKW subunit
participates in the EPSCs found in the CAW region. Immunohistochemistry studies
have found that GluKU/GluKd subunits are enriched in the hippocampus and that
8

knockout of either GluKU or GluKd significantly reduces kainate-induced EPSCs in the
CA\ region of the hippocampus (df, dY).
Importantly, it has been shown that KARs function in long-term potentiation
(LTP) and long-term depression (LTD), processes shown to be involved with learning
and memory formation (dX, ]V). It was shown that blocking presynaptic KARs within
hippocampal synapses can eliminate LTP (]W) while synapses within the perirhinal
cortex require KARs for LTD (]U). It was additionally shown that inhibition of KARinduced LTP in the agranular insular cortex reduced anxiety behavior in mice (]\).
Not long after the physiological functions of KARs were first being
characterized using electrophysiology, KAR knockout models began to be studied. It
was surprising to find that kainate receptor subunit knockout phenotypes displayed
no severe somatic defects, with the only effects found involving cognition and
psychology (df, ][-]X). The behavioral studies performed have shown that GluKW
knockout mice display reduced cognition and fear response, and increased anxiety
(][, ]d). GluKU knockout mice display reduced sociability, cognition and fear
response, an increase in seizures and symptoms of mania (df, ][, ]], ]X). GluK[
knockout mice display symptoms associated with depression and mood dysregulation
and impaired memory formation (]f, ]Y). Knock out of all kainate receptor subunits
(GluKW-d) resulted in compulsive and perseverative behaviors involving grooming, as
well as dysfunction in motor functions (fV).
The lack of severe somatic defects in kainate receptor subunit knockout mice
initially led to limited interest and even questioning of their physiological relevance.
However, mRNA expression profiles of iGluRs in the brain showed that while each
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iGluR subtype has its own unique expression patterns, kainate receptors show
enrichment in areas important for learning, behavior, and anxiety (fW). Additionally, a
recent study identified a gain-in-function mutation in GluKU that causes severe
neurodevelopmental delay and intellectual disability (fU). These results corroborated
the phenotypes of the knockout models.
The abundance of kainate receptors in these areas, combined with their mild
knockout phenotypes and varied functional roles, might position them as the most
ideal iGluR subtype for the treatment of neurological disorders, particularly
psychiatric and psychological disorders. However, progress on this front will require
drugs with the specificity necessary to discriminate between kainate receptors in their
various functional roles.
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Chapter 3: Functional Modulation of Kainate Receptors

Auxiliary proteins
Through their initial functional characterization, it was discovered that kainate
receptors produced currents in heterologous expression systems that differed
significantly from kainate receptor currents recorded in native tissue. Kainate
receptors expressed in heterologous systems showed rapid activation and deactivation
kinetics, while currents recorded in tissue showed rapid activation with prolonged
deactivation kinetics (f\, f[). The mechanisms contributing to these differences were
initially a mystery. However, since that time it has been well established that iGluRs
associate with a number of post-synaptic membrane proteins that alter their
localization and function (fd-ff).
Function-modulating auxiliary proteins have since been discovered for AMPA
and kainate receptors; there are six Transmembrane AMPA receptor Regulatory
Proteins (TARPs) and a Germ cell-Specific Gene W-Like (GSGWL) protein for AMPA
receptors and NetoW and NetoU proteins for kainate receptors (ff-fX). Currently no
auxiliary proteins are believed to be NMDA receptor-specific. Neto1 was initially
thought to modulate NMDA receptors (YV), but was later shown to be specific to
kainate receptors (YW). NetoU was discovered through co-immunoprecipitation
experiments and was found to increase the function by delaying the onset of
deactivation in kainate receptors (ff).
The functional effects of NetoW and NetoU on kainate receptors have been
extensively tested in heterologous systems and show a gain in function that varies
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according to the kainate receptor subunit composition (ff, YW-Y\) (Y[). The gain in
function induced by Neto co-expression results in kinetics with delayed onset of
deactivation and desensitization. These currents behave more similarly to currents
obtained from tissues. These studies have refined our understanding of the in vivo
functional properties attributed to kainate receptors, but it is worth noting that
studies on kainate receptors in tissue are hampered by the difficulty of isolating AMPA
receptor and kainate receptor currents. This is an area that would specifically benefit
from advances in iGluR-modulating compounds that have high specificity.
Currently the structure of Neto proteins has not been solved. It has been
shown biochemically that both Neto proteins consist of two N-terminal extracellular
complement subcomponents Clr/Cls, Uegf, BmpW (CUB) domains followed by a lowdensity lipoprotein (LDL)-like domain, a transmembrane region, and a C-terminal
intracellular domain. Studies have shown that the CUB and LDL domains are involved
in the modulation of kainate receptors and that the second CUB domain is the most
influential on receptor function (YW, Yd). The transmembrane region is believed to
contribute stability to the Neto-kainate receptor interaction and the C-terminal is
known to be involved in trafficking (Y]).
While there are no structural data available for Neto proteins, there are a
number of studies characterizing the structure of other CUB- and LDL-containing
proteins (Yf-Xf). These studies have shown that, W) CUB domains consist of antiparallel beta sheets with conserved disulfide bridges and a conserved tyrosineglutamic acid-aspartic acid-aspartic acid (YEDD) motif, and U) CUB domains mediate
a variety of protein-protein interactions that are amongst classes of proteins that are
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important for developmental regulation. The acidic YEDD motif has been shown to be
the mediator of protein-protein interactions in a variety of other proteins and likely
binds to a basic pocket within the agonist-binding domain or transmembrane linker
regions of the kainate receptor. A similar acidic motif has been identified for AMPA
auxiliary proteins (XY, XX).
While the majority of our current understanding of the structure of Neto
proteins is derived from studies performed on homologous proteins, a coherent
picture of the structure-function relationship can be conceptualized. The functional
data currently available for Neto protein truncations make it clear that like other
homologous proteins, Neto modulation is mediated by extracellular CUB domain
interactions. However, the full structure-function relationship between kainate
receptors and Neto proteins cannot be fully resolved until high-resolution structural
models of the receptor complex are available.

Monovalent ions
iGluRs are known to be functionally sensitive to extracellular ion
concentration. NMDA receptors are inhibited by zinc (WVV, WVW), while AMPA and
kainate receptors can be inhibited or potentiated by divalent ions such as calcium,
barium, magnesium, and zinc (WVU-WVX). However, kainate receptors are unique by
being modulated by the monovalent ions sodium and chloride (fY, WWV-WWd).
The effects of sodium modulation have been well characterized in the
homomeric GluKU receptor with very few studies reported on heteromeric kainate
receptors. It has been thoroughly shown that GluKU homomeric receptors require WdV
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mM NaCl for glutamate-induced currents and replacement with other monovalent
cations like Cs+ nullifies function, reducing currents by YV-XV% as compared to Na+containing currents (WW]). Heteromeric GluKU/GluKd receptors are also sensitive to
CsCl replacement although to a lesser degree with currents reduced by ]d-fd% (WW]).
Molecular dynamic simulations suggest that it is the displacement of the Na+ ion from
the ABD dimer interface that initiates transition from the active to desensitized state
(WWf). Additionally, it has been shown that co-expression of NetoU with both
homomeric and heteromeric receptors reduces their sensitivity to cations. Coexpression with homomeric GluKU showed a ]\% reduction in currents and
heteromeric GluKU/GluKd showed a []% reduction in current, as compared to their
corresponding Na+ currents (WWY).
There are now many studies characterizing the ion sensitivity of KARs in
heterologous systems and precious few on native receptors. However, these studies
have established that homomeric, heteromeric, and auxiliary protein-associated
kainate receptors all require WdV mM Na+ ions in order to exhibit a normal response to
glutamate. Additionally, it has been shown that cultured hippocampal cells (WW])
display kainate receptor-mediated ion sensitivity and that the concentration of
sodium ions in the synaptic cleft is predicted to drop by as much as [V mM during
normal synaptic transmission (WWX). Therefore, it is hypothesized that the sensitivity of
kainate receptors to synaptic sodium concentration would act as a feedback
mechanism in which reduced synaptic sodium levels in an overactive synapse would
cause the kainate receptors to become unresponsive to glutamate release (WWd).
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Unfortunately, this hypothesis will be difficult to test in native systems, however, a
mechanism of this nature should not be discounted.
There are now several converging lines of abductive evidence for a
physiological role involving the modulation of KARs by ions. First, mathematical
modeling of the ion flux during normal synaptic activation produced a conservative
estimate of a [V mM decrease in Na+ concentration (WWX). This would place the affinity
of KARs for Na+ within the dynamic range of ion flux at the synapse. Second, it is
unlikely that a relationship of this nature would be retained throughout evolution
without conferring some kind of advantage to the animal’s phenotype. Third, there are
several other classes of channels and receptors that functionally respond to flux in Na+
ion concentration on either the extra- or intercellular membrane (WUV-WU\). Therefore,
it seems plausible that future experiments will show that the dependence of KARs on
Na+ concentration is a mechanism which adds to the complexity found in the systems
regulating excitatory signaling at certain synapses.
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Chapter 4: Kainate Receptor Structure

Kainate receptors, like all iGluRs, are tetrameric proteins with each subunit
comprising two large extracellular domains, a transmembrane channel and
intercellular C-terminal domain (Figure I). They form functional homomeric and
heteromeric proteins, although the most commonly expressed KARs are heteromeric.
Based on photobleaching and crystallography studies of the isolated ATDs, the
stoichiometry of heteromeric GluKU/Kd KARs is believed to be U:U with GluKU
mediating ATD dimer-dimer interactions (WU[, WUd).
Each subunit is composed of domains that are modular in architecture and are
structurally and functionally distinct: the extracellular amino-terminal domain (ATD),
the extracellular agonist-binding domain (ABD), the transmembrane domain (TMD),
and the intracellular carboxyl-terminal domain (CTD). A unique architectural
characteristic of iGluRs is termed domain swapping, which involves asymmetry in
which subunits associate within the ATD and ABD dimer pairs (Figure I). Linker
regions connect the ATD to the ABD, and the ABD to the TMD. The structure and
function of the individual domains will be discussed in greater detail below.

Amino-terminal domain
The ATDs of the kainate receptor are positioned above the ABDs on the
extracellular side of the membrane (Figure I). They are preceded in the open reading
frame only by a membrane localization peptide signal sequence. These are the largest
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Figure 1. Structural model of the homomeric GluK2 receptor.
(A) Architecture of the GluKU primary sequence. (B) The homomeric kainate receptor
shown under glutamate-bound conditions with each subunit individually colored. The
modular domains are labeled, and the carboxyl-terminal domain is not shown as it has
not yet been resolved. The image is derived from PDB:5KUF resolved using cryo-EM
(29).
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domains within the KAR and have the most diversity in primary sequence (WU]);
however, their functional roles have been difficult to resolve.
Several studies have shown that the individual KAR ATDs are arranged as bilobed clamshell-like structures composed of an RW upper lobe and RU lower lobe (U],
UX). These subunits assemble into dimers to form the dimer of dimer architecture
found in all iGluRs. The similarities of the ATDs to metabotropic glutamate receptor
agonist-binding domains initially left researchers looking for additional ATD specific
ligands; however, no ATD specific modulating ligands have been found for KARs.
While ATD allosteric modulation of receptor function has been shown in the
NMDAR, no allosteric role has been shown for KARs or AMPARs. This led to the idea
that the main role of the ATD involves the initiation of assembly and likely determines
the subunit arrangement of the receptor. This was supported by many studies
showing that the affinities of the various subunit ATD dimers coincide with the
combinations of subunits that form functional channels (WUf-WUX), and studies
showing which subunits likely mediate heteromeric KAR ATD dimerization (WUd).
While these data support the role of ATDs in receptor assembly, it has also been
shown that complete deletion of the ATD in both KARs, AMPARs and NMDARs has
no effect on receptor assembly or function in heterologous systems (W\V, W\W). This
would suggest a different primary role for the ATD in receptor function.
Following these initial studies, functional roles were identified for KAR ATDs
involving receptor and auxiliary subunit localization. Studies have shown that while
GluKU subunits localize to the membrane independent of auxiliary proteins, the
surface expression of auxiliary proteins NetoW and NetoU depend on GluKU ATD-Neto
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interactions (Y]). Additionally, GluKW shows an ATD dependent increase in surface
expression in the presence of NetoW and NetoU (W\U). This suggests that KAR ATDs are
associating with Neto proteins and that interaction can direct receptor and auxiliary
protein localization. Interestingly, the localization of GluKW can also be affected by the
membrane signal sequence even after being cleaved (W\\). These data point to the role
of ATDs in receptor and auxiliary protein localization; however, it is possible that
additional roles remain to be characterized.
While structural studies of the isolated ATDs have shown that KAR ATDs have
a similar architecture as the closely related AMPARs, differences were found when full
length receptor models became available. While both the AMPA and kainate receptor
showed a compact and coupled arrangement between ATD dimer pairs in the apo
state, three classes of arrangements were observed in the glutamate-bound state of the
AMPAR with varying degrees of decoupling between the ATD dimer pairs (U]). This
decoupling was not found in the full-length KAR models of the glutamate-bound state
(U], UX). The glutamate-bound state KAR models showed only small ATD rotations
relative to the antagonist-bound state. The AMPA ATD decoupling has since been
confirmed with smFRET studies (W\[); however, currently there are no complementary
studies available characterizing the conformational dynamics of KAR ATDs in the fulllength receptor.

Agonist-binding domain
The agonist binding domain resides between the ATD and the TMDs in the
extracellular space (Figure I). As described by name, the ABD is responsible for
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binding agonists and initiating the process of activation. It is connected to the ATD
and TMD layers through linker regions that, in the case of the TMD, transfer
conformational changes to the pore region to activate the channel. It was shown
biochemically that the interface within the ABD dimer pairs plays a significant role in
receptor kinetics, but it took full length iGluR models to identify what the structural
implications of this interface involve. While it is now believed that decoupling
between the dimer pairs is the driver of the desensitization process, there have been
studies that question the nature of the decoupling needed for receptor function (\\).
The ABD maintains the highest degree of primary sequence homology among
the iGluR subtypes and the glutamate coordinating residues are maintained between
all three classes, R[XU, T]dX and EdVf in GluKU. Similar to the ATD, the ABD is
arranged in a bi-lobed configuration. The ABD architecture resembles a clamshell with
a cleft that clamps down on agonists, leading to closure of the cleft. The ABD is
composed of two peptide segments within the primary structure named SW and SU. The
SW segment connects with the ATD and terminates at the first transmembrane helix
while the SU segment is positioned between two of the transmembrane helices. The
tertiary folding structure of the SW and SU segments results in an upper DW and lower
DU lobe that comprise the clamshell structure.

Structural studies initially characterized the isolated ABDs of the various KAR
subtypes which gave valuable insight into their role in receptor gating. These studies
showed that different ligands impose varying degrees of cleft closure in the different
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subunits that correlate with their efficacy (W\d-W[V). Subsequent studies using LRET
and smFRET on the all three receptor subtypes confirmed the agonist induced cleft
closure (W[W). These studies also identified the sites responsible for the ion sensitivity
found in KARs.
Studies characterizing the isolated ABD of GluKW and GluKU using X-ray
crystallography identified a Na+ binding pocket driven by atomic interactions between
the Na+ ion and residues QdVX and KdW] (WW\). Not surprisingly, this pocket was found
to reside at the ABD dimer interface and highlights the importance of this interface.
Subsequent molecular dynamic simulations showed that the unbinding of Na+ from
this pocket likely induces the desensitization process in KARs, and that with Na+
present significantly more energy is required to separate ABD dimers (WWf, W[U).
The importance of the ABD dimer interface was further highlighted by separate
studies characterizing the effect of varying mutations within the dimer interface of
GluKU. These studies identified point mutations that both delayed (W[\) and
eliminated desensitization (W[[). Most importantly, they showed that introduction of
a positively charged lysine residue at site Dff] in GluKU induced constitutive activity
in the receptor. These were intriguing results that were later hypothesized to further
explain Na+ sensitivity in KARs. Later, MD simulations showed that the lysine
introduced at position ff] can potentially occupy the Na+ binding pocket and confer
stability between the dimer pairs that prevent decoupling, and entrance into the
desensitized state (WWf).
Importantly, the structural arrangement of the ABD as determined using
isolated domains was subsequently verified by full-length structures of the AMPA,
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kainate and NMDA receptor. However, while there has been a plethora of full-length
receptor models produced for the AMPA and NMDA classes, full-length kainate
receptor models have been difficult to obtain. To date there is a single PDB deposited
in the Research Collaboratory for Structural Bioinformatics (RCSB) structural database
for the antagonist-bound state and two PBD deposited for the agonist-bound state
(U], UX). The antagonist-bound studies could only produce a low resolution (UW Å)
electron density map in which previously resolved crystal structures of the isolated
ABD were fit (UX). The two agonist-bound models are nearly identical showing full
decoupling of the ABD dimers, moving to almost four-fold symmetry within the ABDs.
These structures confirmed many previous findings and have collectively been
used to construct models for the gating mechanism of iGluRs. It is believed that
binding of agonist induces cleft closure at the ABD, which causes strain on the TMD
linkers, leading to channel activation. Once activated, the dimer interface within the
ABD dimers maintains the open channel conformation until that interface gives way
and decouples; KARs being unique in requiring the unbinding of ions for decoupling
to proceed. Once the ABDs decouple, the strain is relieved from the TMDs and the
channel closes, leading to desensitization.
As previously mentioned, the decoupling process is now believed to be the
mechanism initiating desensitization. There is clear evidence for this being the case;
however, structural models of the full-length AMPA and KARs have shown vastly
different conformations under desensitized conditions. Studies of the homomeric
GluAU show three classes of desensitized conformation with varying degrees of
decoupling (U]). Additionally, a study characterizing the effect of crosslinks made
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between AMPAR ABD dimers showed that decoupling is not required for normal
receptor function (\\).
Therefore, the question of decoupling and the conformations that the KAR
ABDs occupy in various conditions remains unclear. The apo state full length models
leave assumptions about dynamics resulting from low resolution electron densities,
while the agonist-bound state differs significantly from agonist-bound AMPA
structures. These questions will be further addressed in this dissertation.

Transmembrane domain
The transmembrane domains of iGluRs are responsible for forming the channel
pore in which ions flow and conferring selectivity to which ions are allowed to pass
through the pore. Before detailed iGluR structural models of became available, their
transmembrane topology was predicted using classical biochemical techniques with
remarkable precision. These studies used glycosylation and protease protection assays
to determine that despite there being four TM regions predicted from analysis of
iGluR primary sequence, there were likely only three transmembrane helices in the
mature protein (W[d, W[]). These findings were later confirmed by structural models.
Structural models of the AMPAR first showed that the TMDs are composed of
three transmembrane helices, MW, M\ and M[, and one membrane reentrant loop MU.
The architecture of the TMD is arranged in pseudo four-fold symmetry and have high
primary sequence homology with both K+ channels and bacterial GluRV K+ selective
channels (U). The transmembrane helices anchor the receptor to the membrane and
play a critical role in channel function.
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The pore is formed by the MU loop, lining the inner cavity, while the M\ helix
line the outer pore cavity (U[). The apex of the MU reentrant loop harbors residue
QdXV which is known to be commonly RNA edited to an arginine residue. RNA
editing at this cite renders the channels impermeable to CaU+ ions, which is critical for
CaU+ induced intercellular signaling mechanisms (W[f). The MW helix runs exterior to
the pore forming MU loop and M\ helix and is likely key structural support, although
mutations with the M\ helix have been found that effect receptor function and cause
intellectual impairment (fU). Surprisingly, the intracellular loop connecting the MU
loop and M\ helix in the GluKd subunit has been shown to contain a trafficking signal
that retains the receptor in the ER (W[Y). The MW and M\ helix with the MU loop forms
the channel domain and this architecture is well conserved through evolution (U[).
The M[ helix lies peripheral to the pore domain and is unique to eukaryotic
glutamate receptors (U[, W[X). It encases the pore domain and interacts with the M\
helix of adjacent subunits. Given its recent appearance in evolution, the function of
the M[ helix has been of interest; however, studies of the M[ helix in AMPA and
NMDA have shown mixed results. It was shown that in the AMPA receptor the M[
helix is involved only in receptor assembly, while it is not critical for assembly in
NMDA but shows effects on gating kinetics (W[X). Currently no studies are available
characterizing the M[ helix in KARs directly.
While the role of the TMD in channel pore formation seems straight forward,
studies have also found that the linker regions connecting the M\ helix to the ABD are
critical in modulation by Neto proteins. These studies found residues in this linker
region that when mutated either attenuate or abolish Neto modulation and reduce the
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ion sensitivity of both homomeric and heteromeric KARs (WWY). These data suggest a
significant role for the M\ linker in auxiliary protein modulation and it is likely that
the TMDs play additional roles in the KAR-Neto interaction; however, further studies
will be required to fully resolve the mechanism of interaction and modulation for Neto
proteins.

C-terminal domain
The C-terminal domain has been the most difficult to resolve structurally
among all iGluRs. Due to high structural dynamics, it has not been fully resolved using
imaging techniques. It is classified as a disordered region that mediates proteinprotein interactions, receptor localization and can modulate function through posttranslational modifications.
Similar to the ATD, trafficking and localization roles have been identified for
the C-terminal domain. It is now understood that alternative splicing and posttranslational modifications are able to affect the subcellular localization of KARs. It
has been shown that GluKU harbors a motif of basic amino acids (CQRRLKH) within
the C-terminal domain that allows for exit from the endoplasmic reticulum (WdV), and
GluKd harbors a similar basic motif (RRRRR) that promotes retention in the ER (WdW).
It is known that the CTDs of KARs are commonly modified through alternative RNA
splicing which can either add or remove these trafficking motifs; therefore, it is
believed that alternative splicing regulates the surface localization of KARs in different
brain regions.
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The effects of the CTD on receptor localization were also highlighted by
studies showing that palmitoylation, phosphorylation and SUMOylation effect
receptor surface expression. Palmitoylation of the GluKU C-terminal domain at CYdY
and CYfW promotes surface localization of the receptor (WdU). Phosphorylation of
serines YfX and YYd on the GluKU and GluK\ C-terminal domain reduces surface
localization of the receptors. It was additionally shown that SUMOylation of GluKU
KYY] can reversibly mediate GluKU surface localization (Wd\).
The CTD has been shown to regulate receptor localization though a variety of
protein-protein interactions. It has been well established that the CTD mediates
interactions important for localization, post-translational modification and receptor
kinetics including but not limited to: CASK, GRIP, GRIPU, mLIN-WV, PICKW, PSDXd
SAPXf, Shank\, Syntenin, Actinfilin, Contactin, Dynamin-W, Dynamitin, Profilin,
SUMO, and Calmodulin (U).
Phosphorylation sites within the C-terminal domain have also been found that
directly affect KAR function. Phosphorylation at serines YUd and Y\f on GluKU results
in potentiation of receptor currents (U). Phosphorylation of site YdXV on GluKU results
in potentiation and increased KAR mediated intercellular CaU+ signaling (Wd[).
Additional phosphorylation sites have been found on GluKW, GluKU and GluK[;
however, testing the functional effects remains to be done.
The structural conformations and dynamics that produce the unique
functional characteristics previously described in the scientific literature for KARs will
be more closely examined in the following chapters.
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Chapter 5: Förster Resonance Energy Transfer in Structural Biology

This chapter is based upon research originally published in Methods in
Molecular Biology. Litwin, D. B., R. J. Durham, and V. Jayaraman. Single-molecule
FRET methods to study glutamate receptors. Methods in Molecular Biology -Glutamate
Receptors. Humana Press. UVWY; WX[W: \-W] © Springer Nature Switzerland AG.

The first biological X-ray crystallography experiments characterizing
myoglobin and hemoglobin not only opened our eyes to the relation of function and
form in biology, but also revealed the utility of structural biology for studying the
evolutionary origins of proteins and for designing useful drugs. X-ray crystallography
and cryo-electron microscopy have since emerged as the front runners in the field of
structural biology and have provided new insight into all fields of biological science.
These techniques will without question continue to lead the way in structural biology.
They both, however, suffer from the limitation that they lack the ability to provide the
complete structural landscape, dynamics in terms of transitions between states and
energetics of transitions between states. This limitation in current methods has
created a niche for studying the structure of unresolvable molecules in addition to
validating and studying the true dynamics of previously resolved X-ray and cryo-EM
models (Wdd, Wd]). Fluorescent spectroscopy, including Luminescence Resonance
Energy Transfer (LRET) and single-molecule fluorescent resonance energy transfer
(smFRET), have emerged as the leading methods for this role (W\[, Wdf, WdY).
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smFRET has become of particular interest to groups studying highly dynamic
proteins and proteins composed of multiple domains acting in concert to perform
mechanically complex motions. Initial efforts have focused on characterizing the
structure of DNA/RNA molecules, DNA/RNA protein complexes, enzymes, signaling
proteins, and ion channels (W\[, Wdf-Wf[). LRET is a complementary FRET method
useful for characterizing large scale conformational arrangements of proteins near
native conditions. iGluRs are a family of ion channels that serve as a perfect subject for
smFRET and LRET studies (W\[, Wdd-WdY, W][, WfV). iGluRs are multimeric, have four
domains with little functional overlap, operate with millisecond kinetics, and have
previously-resolved X-ray and cyro-EM models.
iGluRs are tetrameric proteins with two extracellular domains, a
transmembrane domain (TMD), and an intercellular C-terminal domain. iGluRs are
divided by their selective agonists into AMPA, kainate, and NMDA subgroups, and
some subgroups can express as homomers or heteromers depending on the subunits
used. The extracellular amino terminal domain (NTD) and ligand binding domain
(LBD) are of particular interest for smFRET studies due to the complex
rearrangements proposed during the operation of the protein. smFRET and LRET are
complementary techniques where LRET is able to monitor the average distance
between two fluorophores in an ensemble of molecules and smFRET is able to
characterize the distance and changes in distance at a single molecule level. In this
chapter we will discuss the approach to and execution of smFRET and LRET to study
the conformational dynamics of iGluRs.
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Förster resonance energy transfer
Förster (or fluorescent) resonance energy transfer (FRET) is a term describing
the non-radiative transfer of energy from a donor fluorophore to an acceptor
fluorophore. This relay of energy relies on the overlap of the donor and acceptor
spectra, specifically that the emission of the donor overlaps with the excitation of the
acceptor as seen in Figure T.

Figure 2. Excitation and emission spectrum of Alexa 555 and Alexa 647.
Spectral data for the excitation (Dotted) and emission (Solid) wavelengths of Alexa 555
(Green) and Alexa 647 (Red).
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This phenomenon is distance-dependent where the closer the fluorophore
pairs are in space the more likely they are to FRET. The efficiency of energy transfer is
related to the inter-dye distance (RDA) and the distance of half-maximal energy
transfer for a given fluorophore set (RI), as seen in equation W. The effective distance of
FRET for fluorophores ranges between WV and WVV Angstroms, making FRET ideal for
measuring distances at the protein level.

𝑬=

𝟏
𝟏 + (𝑹𝑫𝑨 ⁄𝑹𝟎 )𝟔

Eq. W

When choosing a fluorophore pair for a FRET experiment the most important
factors to consider are the distance intended to be measured and the RI of the
fluorophore pair. The factors contributing to the RI of a fluorophore pair are the
orientation factor, k; the quantum yield of the donor, ΦD; the spectral overlap integral,
J; and the refractive index of the media, n. The relationship between these values and
the RI is shown in equation U. There are many detailed reviews on the physics of FRET
if additional information is needed (Wfd).

𝟖. 𝟕𝟖𝟓 × 𝟏𝟎𝟓 × 𝒌𝟐 × 𝜱𝑫 × 𝑱
𝑹𝟎 = :
𝒏𝟒
Eq. U
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𝟏;
𝟔

Luminescence resonance energy transfer
LRET is a FRET based technique adapted to utilize organic fluorophores
attached to chosen sites within a protein. The measurement is conducted on a
population of molecules, typically still retained within the cell membrane, while the
sample is kept near native temperature and ionic strength. The disadvantage of LRET,
similar to traditional FRET experiments, is that a measurement is made on a large
population of molecules and the signal obtained is an ensemble their collective
behavior. This is useful when looking at large protein movements and proximity;
however, these measurements provide an ensemble average and the complete
structural landscape along with transitions between the states cannot be resolved.

Single-molecule Förster resonance energy transfer
In order to circumvent the previously mentioned limitations of traditional
FRET and LRET experiments, total internal reflection microscopy (TIRF), U-photon
excitation microscopy, and confocal microscopy have been adopted to bring
measurements to the single molecule level of both immobilized and freely diffusing
molecules as well as in living cells.
These advantages of smFRET have vastly improved our ability to characterize
sub-millisecond dynamics in protein, DNA, and RNA in addition to resolving protein
subunit stoichiometry. However, collecting data with such detail does not come
without its caveats. Data analysis has become the most difficult part of smFRET and
methods for collecting and analyzing data have had to evolve. The advent of
multiparameter fluorescence detection (MFD), time correlated single photon counting
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(TCSPC), pulsed interleaved excitation (PIE), and fluorescence correlation
spectroscopy (FCS) have vastly improved the potential quality of smFRET data,
discussed further in the data analysis section. Instruments capable of collecting data
using MFD, FCS, PIE and TCSPC simultaneously are now available. The collective use
of these techniques has greatly improved our ability to resolve the inherent
complications of fluorophore photophysics and movements from true FRET signal
(Wf]). In this chapter we will focus smFRET and LRET measurements using confocal
imaging and lifetime-based measurements respectively.

Experimental design
The design of LRET and smFRET experiments are similar. Any requirement
unique to one or the other will be noted. When designing a LRET or smFRET
experiment studying iGluRs, the labeling strategy used will depend on the subunit
being studied and the intended measurement. The main design step is site selection
and considerations here will be the subunit arrangement, distance to be measured,
and fluorophore pairs.
In a heteromeric iGluR such as the NMDA receptor there will be two sets of the
subunits arranged in a defined orientation. By taking this into account it is possible to
pick a surface-exposed amino acid position on either of the subunits used that is V.dWX the RI of the fluorophore pair. In this case labeling with a site-specific cysteine is
recommended. For example, in Figure W the heteromeric NMDA receptor is shown
with transmembrane residues selected to measure the change in distance across the
axis of the pore. Only the highlighted residues will be labelled and measured.
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Figure 3. Model of the NMDA receptor showing an ideal FRET measurement
in a heteromeric receptor.
A structural model of the NMDA receptor showing phenylalanine 554 (Red) as the
fluorescent labeling site for measurements across the ion pore (PDB:5UP2) (27), side
view (left) and top view (right).
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If using a homomeric iGluR such as in homomeric AMPA receptors, choosing
sites for study could be more complicated. This is the result of having the site of
interest on all four subunits. In this case, it is required that the site of interest has one
high FRET distance V.d-WX the RI and one distance ideally well above the RI of the
fluorophore pair for a given state. As seen in Figure Y, the site chosen will have a
primary FRET distance of [W Å with an additional distance of ][ Å across dimer pairs.
This ensures that the main FRET component, [W Å, is V.d-WX the RI and will be easily
resolved from the longer component. In this chapter we will focus on the use of
heteromeric iGluRs.
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Figure 4. Model of the AMPA receptor showing an ideal FRET measurement in a
homomeric receptor.
A structural model of the AMPA receptor showing aspartic acid 473 (Red) as the
fluorescent labeling site for measurements between the LBDs (PDB:5VHZ) (28), side
view (left) and top view (right).
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When studying iGluRs using smFRET, immobilizing the protein on slide via
antibody pull-down is preferred. Any antibody with high specificity will work; it is
recommended, however, to introduce an affinity tag at the C-terminus to minimize
the effect of antibody binding on protein function. When using a new antibody it is
critical to run western blots to confirm specificity of the antibody. When performing
LRET, antibodies are only required for validation of expression.

Cysteine labeling
The best option for fluorophore labeling for both LRET and smFRET is by
introducing a cysteine at the site of interest. This allows use of many commonly
available thiol-reactive fluorophores and retains high expression levels. This does
however require that all the native non-disulfide bonded cysteines be mutated to
provide a clean background. Once this is achieved, the expression and function of the
cysteine-less construct must be verified. When approaching the design of an
experiment it is ideal that one choose sites that will show a change in distance and will
also have one effective FRET distance. It is not always possible to achieve the ideal
labeling strategy in every region of the protein, or the measurement may need to be
made within the subunit itself. If either of these is the case, utilizing unnatural amino
acids allows for additional site specific labeling.

Unnatural amino acid labeling
Unnatural amino acids are advantageous in that one retains the native coding
sequence of the protein; however additional plasmids must be maintained for use and
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expression of the protein needs to be verified by western blotting and function of the
protein verified. The principle behind utilizing unnatural amino acids is using a tRNA
and aminoacyl-tRNA synthetase that have been artificially evolved to suppress the
amber stop codon (TAG). The TAG can be inserted by mutagenesis into any position
along the protein and, when co-transfected with plasmids containing the tRNA and
aminoacyl-tRNA synthetase, will be suppressed by the incorporation of the unnatural
amino acid into the peptide chain (Wff).

LRET sample preparation
HEK293T cells are transiently transfected according to manufacture’s protocol and
maintained in DMEM. The transfected cells are collected and washed three times in
extracellular buffer containing 160 mM NaCl, 1.8 mM MgCl2, 1 mM CaCl2, 3 mM KCl,
10 mM glucose, and 10 mM HEPES (pH 7.4). The washed HEK cells are then labeled
with 400 nM donor and 100 nM acceptor fluorophores in 3 ml extracellular buffer,
rotating at room temperature in the dark for 1 hr. The donor fluorophore typically
used is terbium chelate (Invitrogen), and the acceptor fluorophore used is fluorescein
maleimide (Thermo Fisher Scientific), for cysteine mutants. After labeling, cells are
washed and resuspended in 2 ml extracellular buffer and are ready for use in LRET
measurements.

Data collection LRET
A cuvette-based system consisting of a fluorescence lifetime instrument (EasyLife
L;Hoiba) and analysis software (Fluorescan 5.5; Optical building blocks) is needed for
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LRET measurements. Samples should be excited at 337 nm when using terbium
chelate. Emission is detected at 545 nm for donor-only samples, at 515 nm for
fluorescein-labeled samples. LRET measurements should be taken in triplicate for a
given condition followed by scans after Factor Xa protease cleavage to quantitate the
samples’ background signals without the labeled receptors’ contribution to the signal.

Data analysis LRET
Fluorescent decay plots obtained for given conditions and the background for
that condition should be plotted in graphing software like Origin (OriginLab) and
averaged, and then the background can be subtracted from the full signal. Following
background subtraction, the resulting decay plots are fit to exponential decay
functions thereby quantitating the decay lifetime of the acceptor fluorophore. Error in
the distance estimates is calculated by propagating the errors in the donor and
acceptor lifetimes using the Error Propagation Calculator developed by Thomas Huber
in the Physics Department of Gustavus Adolphus College. Lifetimes should also be
quantitated for samples labeled with only the donor (tD) and samples labeled with
both donor and acceptor (tDA), to be used to calculate the distance between the
fluorophores using the Forster equation:

𝑹 = 𝑹𝟎 (

t𝑫𝑨
𝟏
) ;𝟔
t𝑫 − t𝑫𝑨

Eq. 3
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where R is the distance between donor and acceptor fluorophore, R0 is the distance
yielding half-maximal energy transfer for a given fluorophore pair (45 Å for terbiumfluorescein), tD is the measured lifetime of the donor when bound to the protein and
without acceptor fluorophore present, and tDA is the lifetime of the donor fluorophore
when bound to the protein and transferring energy to the acceptor fluorophore, which
can be measured as the lifetime of the sensitized emission of the acceptor. Final
lifetime values for given conditions are obtained by averaging the backgroundsubtracted lifetime values per day.

smFRET sample preparation
HEKUX\T cells should be transiently transfected, WV µg per WV cm plate for
JetPrime reagent. One day post-transfection, cells from two WV-cm dishes are
harvested and washed with extracellular buffer and labeled for W h at room
temperature with [VV nM of donor fluorophore Alexa ddd maleimide (ThermoFisher)
and [VV nM of acceptor fluorophore Alexa ][f maleimide (ThermoFisher) in \ mL
extracellular buffer. This concentration of fluorophore was determined to be optimal
for single donor and single acceptor labeling. After washing, the labeled cells are then
solubilized for W h at [ °C in solubilization buffer (SB) consisting of phosphate-buffered
saline, W% lauryl maltose neopentyl glycol (Anatrace), U mM cholesteryl hydrogen
succinate (MP Biomedicals), and ¼ protease inhibitor tablet (Pierce). The
unsolubilized debris is then spun down for W h at WVV,VVV × g at [°C, and the
supernatant is used as the smFRET sample. Samples are then diluted W:U in cold SB
before application.
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Data collection smFRET
A confocal microscope is used for data collection. An example confocal system
that is used for such smFRET experiments is the PicoQuant MicroTime UVV
Fluorescence Lifetime Microscope. Scan a UV µm x UV µm area of the slide to identify
molecules for imaging, then record the fluorescence intensity of each molecule until
the donor and acceptor fluorophores undergo photobleaching. Example traces
showing anticorrelation between the donor and acceptor are shown in Figure Z.
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Figure 5. Representative smFRET fluorescence and efficiency traces.
(a) A representative smFRET trace measured from an agonist binding domain of
AMPA receptor showing raw trajectories of the donor (blue) and acceptor (red)
photons as a function of time. (b) The resulting calculated FRET trajectory (green) and
its denoised counterpart (black). This research was originally published in the Journal
of Biological Chemistry (157) © the American Society for Biochemistry and Molecular
Biology.
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To ensure that the fluorescence is from the receptor tagged at the site of
interest, one will need to perform control experiments with no protein, protein with a
single labeled site, and protein with two labeled sites as shown in Figure [.

Figure 6. smFRET slide imaging showing the specificity of labeling strategies.
smFRET slide imaging showing the specificity of the labeling strategy. Blue pane
corresponds to donor channel, and brown pane is FRET channel (acceptor frequency
emission with donor frequency excitation). As seen in (a) there is no labeling when
protein is not applied to the slide. In (b), the appearance of donor signal is seen when
protein with single cysteine labeled with fluorophores is applied to the slide. In (c),
the appearance of FRET is seen when protein with two cysteine labeling sites labeled
with fluorophores is applied to the slide. This research was originally published in the
Journal of Biological Chemistry (178) © the American Society for Biochemistry and
Molecular Biology.
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Data analysis smFRET
For data analysis, the donor and acceptor data must be exported as ASCII files.
Then, corrected FRET efficiencies (EA) can be calculated according to equations [ and
d:

𝑬𝑨 = (𝟏 + 𝜸

𝑰𝑫 ?𝟏
)
𝑰𝑨

Eq. 4

𝜸=

𝜼𝑨 𝜱𝑨
𝜼𝑫 𝜱𝑫

Eq. 5

where ID is the intensity of donor fluorescence, IA is the intensity of acceptor
fluorescence, γ is a correction factor accounting for the efficiencies of the detectors
used and for the quantum yield of the fluorophores, η is the efficiency of a given
detector, and Φ is the quantum yield of a given fluorophore. Once corrected FRET
efficiencies have been calculated, plot the histograms depicting the distribution of
various FRET efficiencies and analyze those histograms using any graph software.
To identify states in the single molecule trajectory, the Hidden Markov
Modeling (HaMMy) analysis (WfX) or the State Transition and State Identification
(STaSI) analysis can be used (WYV).
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Conclusions
With the incredible advances made in cryo-EM electron detector technology in
the past WV years, there is no question that the number and quality of cryo-EM based
molecular structures will continue to grow. These models provide the foundation for
our understanding of the molecular world; however, limitations in the conclusions
that can be made concerning the dynamics involved in complex molecular functions
make it critical that experiments capable of characterizing dynamics be executed in
parallel. Through the use of MD simulations, molecular models can be integrated with
structural dynamic experiments and provide a full picture of underlying biophysical
mechanisms.
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Chapter 6: FRET Studies of the GluK2 Homomeric Receptor

This chapter is based upon research originally published in Scientific Reports.
Litwin, D. B., E. Carrillo, S. A. Shaikh, V. Berka, and V. Jayaraman. The structural
arrangement at intersubunit interfaces in homomeric kainate receptors. Scientific
Reports. UVWX; X(W):]X]X © Springer Nature Publishing AG.

As discussed in chapter [, several structures are now available for the different
subtypes of the glutamate receptor (U[, U]-\U, WYW-WY\). These structures show that the
receptor is organized as a dimer of dimers and ligands bind to the clamshell-like
agonist-binding domain (Figure ]A). The binding of agonist induces a cleft closure
conformational change which, when propagated to the transmembrane segments, is
thought to lead to activation. The activated state also exhibits a coupled dimer
interface at the agonist-binding domain; decoupling of the dimer interface relieves the
stress on the transmembrane segments induced by the cleft closure, resulting in
desensitization (U[, U]-UX, \W, \U, WWf, WYW, WYU).
However, most of these structures are for the AMPA and NMDA subtype of the
glutamate receptors. Only three full-length kainate receptor structures are available,
two in the antagonist-bound form (Ud, UX) and two in the agonist-bound form
thought to be in the desensitized state (U], UX). These structures fall into two classes,
the antagonist-bound structure with tight coupling at the interfaces at both the
amino-terminal domain and agonist-binding domain, and the agonist-bound structure
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Figure 7. Structural arrangement of the GluK2 receptor and its FRET sites.
(A) Cryo-EM structure of GluK2 (PDB:5KUF) showing amino-terminal domains
(ATD), agonist-binding domains (ABD), and transmembrane domains (TMD). (B and
D) GluK2 ATD and ABD in antagonist-bound form (PDB:5KUH). (C and E) GluK2
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ATD and ABD in agonist-bound form (PDB:5KUF). Labeling sites are shown as black
spheres.

of the kainate receptor showing large decoupling at the agonist-binding domain with a
near four-fold symmetry due to extreme decoupling between the dimers (Figure ]A
and E). The closely related AMPA receptor structure exists in multiple conformations
with varying degrees of decoupling at the amino-terminal and agonist-binding domain
interfaces in the apo (Uf) and agonist-bound forms (U[, U]-UX, \W, \U, WYW, WYU). Thus,
the question remains as to whether there is an inherent difference in the structure of
kainate receptor relative to that of the AMPA receptor or is the perceived lack of
heterogeneity due to the limited structural data currently available.
Kainate receptors are also unique among the glutamate receptor subtypes in
exhibiting modulation by Na+ ions. Functional studies have shown that kainate
receptors require the presence of Na+ and Cl- ions at physiologically relevant
concentrations to mediate glutamate-gated channel opening and that substitution of
the sodium ions with other monovalent cations, such as cesium ions, results in the
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inhibition of the receptor-mediated currents (WWV, WWU-WWd). Structural and
computational studies on the isolated agonist-binding domain, as well as indirect
functional studies, indicate that the dimer interface is the binding site for the Na+ (WWV,
WWU-WWd, WWf, W[U, WY[). Given that the structural insight is based on the isolated agonistbinding domain, what is still needed to build on this foundation is insight into the
modulation of the conformational and energy landscapes at this dimer interface by
ions in the full-length receptor.
Recently, advances in fluorescence microscopy have made it possible to study
the conformation-energy landscapes of a variety of molecules. When used in
combination with previously published structural models, fluorescence resonance
energy transfer (FRET) allows for the measurement of conformational heterogeneity
and the energetic quantitation of dynamics within molecules (W\[, Wdd-WdY, W]V, WfV,
WfY). Herein we use this methodology to study the homomeric full-length kainate
receptor at sites that are able to monitor proximity within the amino-terminal domain
and within the agonist-binding domain dimer interfaces that are expected to show the
conformational variability associated with desensitization and ion modulation. The
smFRET studies presented herein provide the first look into the structural
arrangement and dynamics associated with full-length kainate receptor antagonistbinding, activation, desensitization, and sodium modulation, specifically focusing on
the interfaces which are thought to be critical in these processes. One limitation of
this methodology is the millisecond (d ms bins) resolution of the method, thus rapidly
fluctuating conformations will appear as an average.
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Results

Functional characterization of FRET constructs and selection of sites
The GluKUEM construct used previously in cyro-electron microscopy studies
(U], UX) was modified for FRET experiments to allow for site-specific labeling by
mutating the non-disulfide bonded cysteines CXW, CWXX, C[\U to serines (GluKU*). Site
U]] and site [fX were chosen to introduce the donor and acceptor fluorophores based
on two requirements (Figure ]). First, the sites reflected the large-scale
conformational changes expected based on the currently available end state structures
of the antagonist- and agonist-bound forms of the kainate receptor and closely related
AMPA receptor. Second, the sites are arranged such that the distance being
investigated (highlighted as darker line) has high FRET efficiency for the FRET donoracceptor pair, all other distances are expected to have less than Wd% FRET efficiency
and if present should occur well separated from the distance of interest (W\[, WfY, WYd,
WY]). GluKU*-U]]C and GluKU*-[fXC constructs were characterized using
electrophysiology and show kinetics similar to those of the wild type receptor (Figure
^). Additionally, these two mutants show a similar decrease in currents upon
exchange of Cs+ for Na+ in the extracellular buffer (Figure ^).
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Figure 8. FRET construct characterization for homomeric studies.
(A) Representative whole-cell recordings for wild-type GluK2, and fluorophore-labeled
GluK2*266C, GluK2*479C and GluK2*479C-D776K with extracellular 150mM NaCl
(black traces) or 150mM CsCl (red traces) and in the presence or absence of 10mM
glutamate. (B) Bar graph showing currents obtained using Cs+ buffer normalized to
currents obtained using Na+ buffer.
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Conformational changes at the amino-terminal domain
In order to compare measurements made with the receptor retained in a lipid
bilayer with those obtained under detergent solubilized conditions using smFRET,
LRET measurements were performed on construct GluKU*U]]C. The LRET fluorescent
decay plots for construct GluKU*U]] under apo conditions show a lifetime of ]WX µs,
which corresponds to a distance of [U ± V.[f Å. The LRET plots for construct
GluKU*U]] under glutamate-bound conditions show a lifetime of d]X µs, which
corresponds to a distance of [W ± V.\X Å, Figure a. These data show that there is no
significant change in distance at this site between the apo and glutamate-bound
conditions.
Denoised smFRET efficiency histograms for the GluKU*-U]]C receptor and
representative smFRET traces are shown for the apo, antagonist and glutamate-bound
states in Figure IbA, B and C, respectively. The denoised smFRET efficiency
histogram was obtained using traces that exhibited single donor and single acceptor
photobleaching, Figure TbA, thus ensuring that the efficiency corresponds to a single
donor-acceptor distance. Additional representative smFRET traces are provided in
Figure II. The smFRET trajectories were analyzed using the statistical software suites
STaSI (WYV) (Figure Ib A, B and C) and HAMMY(WfX) Figure TbB. STaSI determines
the number of states within a data set using a t-test to identify step transitions and a
minimum description length algorithm to determine the optimal number of states.
HAMMY creates a model of the step transitions and states that best describe a data set
using hidden Markov modeling. A comparison of different software by Sigel and
coworkers showed that STaSI is more accurate in predicting number of states and
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a

b

Figure 9. LRET data for the N-terminal domain construct GluK2*266C.
Acceptor fluorophore decay plots for GluK2*S266C in the presence of 150 mM NaCl
under (a) apo conditons and (b) glutamate-bound conditions. Measurements were
made using terbium chelate (donor) and fluorescein (acceptor).
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Figure 10. smFRET efficiency histograms for construct GluK2*266C.
Conformational landscape of the dimer-dimer interface at the amino-terminal domain
at site 266 in full length homomeric GluK2 receptors. Representative smFRET traces
and FRET histograms showing fractional occurrence as a function of FRET efficiency
in (A) the apo state (data from 47 molecules), (B) presence of 1mM UBP310 (data from
29 molecules) and (C) presence of 1mM glutamate (data from 50 molecules). Traces
show observed signal in pink, denoised signal in blue, and state transitions in black.
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Figure 11. Representative FRET efficiency traces for constuct GluK2*266C.
Representative FRET efficiency traces showing the observed acceptor (green), donor
(blue) and FRET efficiency (black) in the FRET region for site 266 in the (A) apo state
(B) glutamate-bound state, and (C) UBP310 bound state. The wavelet based denoised
data is shown in neon green, cyan and magenta overlaid on the observed data.
state efficiencies (WYf). However, STaSI uses denoised data while HAMMY is
performed on observed data, hence we have used both to ensure that denoising is
accurate.
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Under apo conditions three FRET efficiency peaks are observed at V.]X, V.Y\
and V.XU corresponding to distances of [d Å, \X Å, and \[ Å. The smFRET histogram
for the antagonist UBP-\WV, on the other hand, shows a single peak at V.fX FRET
efficiency indicating a single conformation, which corresponds to a distance of [W Å.
The distances of [d Å in the apo and [W Å in antagonist-bound state are similar to the
distances of [d Å (PDB:dWEN(\W), dLIB(WY\), \KGU(U[), [U[G(UY)) and [U Å
(PDB:[UUP(Uf)) at equivalent sites seen in the antagonist and apo state structures of
closely related AMPA receptors. In the glutamate-bound state two FRET efficiency
peaks are observed at V.f and V.Y\ that correspond to distances [[ Å and \X Å . These
distances are similar to the [] Å (PDB:dVHZ(\U), [U[F(UY)) and [V Å
(PDB:[UUQ(Uf)) seen in the glutamate-bound structures of closely related AMPA
structures, and [] Å in the agonist-bound structure of kainate receptors
(PDB:[UQQ(U])). The spread of states observed in the amino-terminal domain in the
glutamate-bound state of kainate receptors does not show large decoupling as seen in
Class II and Class III agonist-bound structures of AMPA receptors (Wd).

Conformational changes at the agonist-binding domain
To characterize the conformational and energy landscape at the dimer
interface of the agonist-binding domain, smFRET experiments were conducted using
GluKU*-[fXC. smFRET histograms for mutant GluKU*-[fXC in the apo, antagonist,
and glutamate-bound states in the presence of Na+ are shown in Figure ITA-C.
Additional representative smFRET traces are provided in Figure IW and corresponding
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HAMMY fits for the data are show in Figure TbC. The apo state in the presence of Na+
has a single peak in histogram showing a single state with a FRET efficiency of V.YX,
corresponding to a distance of \] Å. The antagonist-bound state also shows a single
peak but with a more narrow half width indicating a more rigid protein. The FRET
efficiency is also higher V.Xd corresponding to a distance of \W Å. These data are
representative of a coupled agonist-binding domain dimer interface and similar to the
\\ Å seen in the antagonist-bound structure of kainate receptor (PDB:dKUH(UX)).

The smFRET histogram in the presence of glutamate and Na+, on the other
hand, shows five FRET efficiencies, (Figure ITC), corresponding to distances of dd Å,
[X Å, [[ Å, \X Å and \\ Å. These distances are similar the two distances of df Å and dW
Å between the dimers in current kainate receptor models (PDB:[UQQ(U]),
dKUF(UX)). However, a large fraction of the receptors show a less decoupled interface
and these shorter distances have been observed in AMPA receptors, with structures
showing a distance of [] Å (PDB:dVHZ(\U), dVOV(\V)) and a distance of \X Å
(PDB:[UUQ(Uf), [U[F(UY)) at the equivalent sites.

smFRET was next used to characterize the active state structural dynamics of
the kainate receptor using a Dff]K mutant, which stabilizes the receptor in the open
state (W[[) (Figure ITD). Additional representative smFRET traces are provided in
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Figure 12. smFRET efficiency histograms for construct GluK2*479C.
Conformational landscape at dimer interface at the agonist-binding domain at site 479
in full length homomeric GluK2 receptors. Representative smFRET traces and FRET
histograms showing fractional occurrence as a function of FRET efficiency in presence
of 150 mM NaCl in the (A) apo state (data from 57 molecules), (B) presence of 1mM
UBP310 (data from 28 molecules), and C) presence of 1 mM glutamate (data from 66
molecules), and (D) D776K mutant in the presence of 1mM glutamate (data from 47
molecules).
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Figure 13. Representative FRET efficiency traces for constuct GluK2*479C.
Representative FRET efficiency traces showing the observed acceptor (green), donor
(blue) and FRET efficiency (black) in the FRET region for site 479 in the (A) apo state
(B) glutamate-bound state, and (C) UBP310 bound state. The wavelet based denoised
data is shown in neon green, cyan and magenta overlaid on the observed data.
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Figure IY. The smFRET data show that for this open-state stabilized receptor, the
primary state has a FRET efficiency of V.X\, which corresponds to a distance of \\ Å.
While both the apo state and the Dff]K glutamate-bound state have primarily one
main conformation, the striking difference between the two is the half width of these
states. The half width is narrower in the Dff]K glutamate-bound state relative to that
in the apo state of the receptor, indicating that the protein is more rigid in the Dff]K
glutamate-bound state relative to the apo state of the receptor.
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Figure 14. Representative FRET efficiency traces for constuct GluK2*479CD776K.
Representative FRET efficiency traces showing the observed acceptor (green), donor
(blue) and FRET efficiency (black) in the FRET region for site 479 in the D776K
background for glutamate bound state in NaCl. The wavelet based denoised data is
shown in neon green, cyan and magenta overlaid on the observed data.
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Conformational modulation by ions
To study the structural effects of ion modulation, smFRET and LRET
measurements were performed with the kainate receptor in the presence of Cs+
(replacing the Na+ ions). Cs+ was chosen as there are extensive electrophysiological
studies performed under these conditions showing large decreases in currents (WWV,
WWU-WW[). Thus, direct correlations can be made between the smFRET data and this
large body of functional studies. Changes are observed between the Na+ and Cs+
conditions in the apo state of the receptor.
When Na+ is replaced with Cs+ a LRET lifetime of d]V µs is found for the apo
state at site U]], which corresponds to a distance of [W ± V.UU Å, Figure IZ. For the
glutamate-bound state a lifetime of ]UX µs is found, which corresponds to a distance
of [U ± V.Wf Å. These data show that similar to Na+ containing conditions, there are no
significant changes in distance at this site between that apo and glutamate-bound
conditions. The lifetimes obtained under these conditions correspond to distances of
[W Å (d]X and d]V µs) and [U Å (]WX and ]UX µs). These distances fit well with the
distances obtained for this site using smFRET under conditions contain either Na+ or
Cs+.
The smFRET denoised histograms show three efficiency peaks in the presence
of Cs+ (Figure I[A) for site [fX, corresponding to distances of [Y Å, [W Å, and \[ Å,
respectively. Additional representative smFRET traces are provided in Figure I]. The
Cs+ conditions are in contrast to the apo state of the receptor in the presence of Na+,
where the receptor exists primarily in the high FRET more coupled state. The smFRET
denoised traces for the glutamate-bound state in the presence of Cs+ (Figure I[B)
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b

Figure 15. LRET data for the amino-terminal domain construct GluK2*S266C.
Acceptor fluorophore decay plots for GluK2*S266C in the presence of 150 mM CsCl
under (a) apo conditons and (b) glutamate-bound conditions. Measurements were
made using terbium chelate (donor) and fluorescein (acceptor).
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Figure 16. smFRET efficiency histograms for construct GluK2*479C and
GluK2*479C-D776K in the presence of CsCl.
Conformational landscape of the dimer interface at the agonist-binding domain at site
479 in full length homomeric GluK2 receptors. Representative smFRET traces and
FRET histograms showing fractional occurrence as a function of FRET efficiency in
presence of 150 mM CsCl in the (A) apo state (data from 55 molecules), (B) presence of
1 mM glutamate (data from 52 molecules), and (C) D776K mutant in the presence of
1mM glutamate (data from 55 molecules).
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Figure 17. Representative FRET efficiency traces for constuct GluK2*479C in the
presence of CsCl.
Representative FRET efficiency traces showing the observed acceptor (green), donor
(blue) and FRET efficiency (black) in the FRET region for site 479 in the (A) apo and
(B) glutamate-bound stat in the presence of 150 mM CsCl. The wavelet based denoised
data is shown in neon green, cyan and magenta overlaid on the observed data.
Representative FRET efficiency traces showing the FRET regions for site 479.

64

showed FRET efficiencies corresponding to five distances of dW Å, [Y Å, [[ Å, [V Å,
and \d Å. These distances in Cs+ are similar to the distances of dd Å, [X Å, [[ Å, \X Å
and \\ Å observed in Na+. However, the occupancies of these states are significantly
different, with higher occupancy of lower FRET states in Cs+ relative to Na+. These
results indicate that while the receptor occupies similar conformational states in both
Cs+ and Na+, the more decoupled states have higher occupancy in the presence of Cs+.

The D]]fK mutant on the other hand did not show any significant shift in the
states between Na+ (Figure ITD) and Cs+ (Figure I[C), additional representative
traces shown in Figure I^. Given that the activated state requires coupling between
the dimers, the larger fraction of the receptors in the low FRET decoupled states in the
apo state of the receptor in the presence of Cs+ would contribute to the decrease in
activation observed in the presence of Cs+.
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Figure 18. Representative FRET efficiency traces for constuct GluK2*479CD776K in the presence of CsCl.
Representative FRET efficiency traces showing the observed acceptor (green), donor
(blue) and FRET efficiency (black) in the FRET region for site 479 in the D776K
background for glutamate bound state in CsCl. The wavelet based denoised data is
shown in neon green, cyan and magenta overlaid on the observed data.
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State transitions and energy landscape
In addition to providing the state occupancy, the smFRET trajectories allow for
the direct observation of transitions between different states, specifically in the
desensitized and Cs+ conditions, as exemplified by the representative traces in Figures
IT and I[. Based on these data, we have obtained transition maps showing the relative
number of transitions between states (Figure Ia). The data show that within the
agonist-binding domain, transitions primarily occur between states of nearest FRET
efficiency, whereas transitions between non-adjacent states are less common. The
probability of observing these non-adjacent state transitions is higher in the presence
of Cs+ under desensitizing conditions, which suggests a lower energy barrier for the
transitions. These data are consistent with the energy maps and show that in the
presence of both glutamate and Na+, the lowest energy barrier of transition is between
the high-FRET states with efficiencies of V.X\ and V.YU. However, in the presence of
both glutamate and Cs+, the activation energy barriers are similar across all states.
These data indicate that with Na+ present the receptor is more stable in the coupled
state and requires more energy to transition into states with increasing distance, and
that in the presence of Cs+ the receptor is able to move across states with relatively
low energy barriers.

67

Figure 19. Transition maps and free energy diagrams based on the smFRET data
at site 479.
Transition maps showing transitions from a given FRET efficiency to a given FRET
efficiency (i) and free energy associated with the transitions (ii) in (A) 150 mM CsCl,
(B) 150 mM NaCl and 1mM glutamate, and (C) 150 mM CsCl and 1mM glutamate.
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Figure 20. Representative trace and Gaussian fit histograms for homomeric
studies.
(A) Representative traces showing single photobleaching step for donor and acceptor
and anticorrelation showing that the donor and acceptor are from FRET pairs.
Observed histograms with data being fit using Gaussians based on HAMMY analysis
for (B) GluK2*S266C (i) in apo conditions, (ii) in the presence of 1mM glutamate and
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(iii) in the presence of 1 mM UBP310. (C) GluK2*479C with 160 mM NaCl and in apo
conditions (i), (ii) in the presence of 1mM glutamate and (iii) in 150 mM NaCl with
1mM UBP310. (D) GluK2*479C with 150 mM CsCl and in the absence (i) and presence
(ii) of 1mM glutamate.(E) GluK2*479C-D776K with (i) 150 mM NaCl and 1mM
glutamate and (ii) 150 mM CsCl and 1mM glutamate.
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Discussion
There are several X-ray crystallographic structures of isolated domains for all
subtypes of the ionotropic glutamate receptor. Studies of the full-length receptor,
however, have been primarily focused on the AMPA and NMDA subtypes (U[, U], Uf,
UX, \U, WYW, WYU), with only an antagonist- and agonist-bound structure of the fulllength kainate receptor. The structures (U[, U]-UX, \W, \U, WYW, WYU), spectroscopic
investigations (Wdf, WdY, W]V, WfV, WfY, WYY, WYX), and molecular dynamic simulations of
AMPA and NMDA receptors (WXV-WXU) show that the protein occupies multiple
conformations under any given condition and such diversity in conformation is
consistent with the diversity of states seen in single channel recordings of these
receptors. More importantly, these studies suggest that the receptor function is
dictated to a large extent by conformational selection. However, this structural
heterogeneity has not been shown for the kainate receptors. Herein we have used a
combination of LRET and smFRET measurements to resolve the conformational
landscape of the full-length kainate receptor under physiologically-relevant conditions
in the antagonist-bound, apo, active, and desensitized states and additionally have
identified the changes in kainate receptor dynamics induced by Na+ modulation.

The resting state
Detailed structural models of the apo state of the kainate receptor have been
particularly elusive; the only structural information with respect to the resting state
has been derived from the structure of the antagonist-bound form of the receptor. The
smFRET data show that under apo conditions in the presence of Na+, the agonist71

binding domain exists primarily in one conformation, with a distance consistent with
a coupled dimer interface, but structural heterogeneity is observed at the aminoterminal domain with a small distance range. This is similar to what is seen in the
AMPA receptors (\W). Additionally, the distances corresponding to the FRET
efficiencies obtained match well between LRET and smFRET measurements. In the
presence of Cs+ ions, on the other hand, the dimer interface exhibits both coupled and
decoupled conformations. Because the active state requires the agonist-binding
domain interface to be coupled, this decoupled dimer interface would require more
energy to be converted to the active state and can account for the lower receptor
activation observed in the presence of Cs+.

The antagonist-bound state
The smFRET histograms for the antagonist-bound state at both the aminoterminal domain and agonist-binding domain show single states that are similar to the
most probable state seen in the resting apo state. However, the antagonist-bound
state is clearly more rigid at these interfaces, exhibiting a smaller half width even in
this single state.

The active state
The smFRET data on the Dff]K mutant, which stabilizes the receptor in the
open, activated state, show that the agonist-binding domain dimers remain primarily
coupled in the active state and that substituting Cs+ for Na+ has no effect. These data
are consistent with the structure and molecular dynamics simulations of the Dff]K
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mutant that show the introduced lysine can occupy the Na+ binding site (WWf),
eliminating the requirement for Na+ to activate. Furthermore, these data are
consistent with the electrophysiological measurements which show a similar extent of
activation under both Na+ and Cs+ conditions (WWf). The smFRET data showing a tightly
coupled active state in the D]]fK mutant with a much smaller full width at half
maximum relative to the apo state, indicates that this structural rigidity at the
interface allows for the channel to be constitutively active with high probability of
opening as seen in single channel recordings (WWf).

The desensitized state
Current structures of kainate and AMPA receptors under desensitizing
conditions show significant differences between the two closely-related subtypes. At
the amino-terminal domain, the kainate receptor showed minimal decoupling, while
the AMPA receptor showed varying degrees of decoupling. At the agonist-binding
domain the kainate receptors showed complete decoupling with the receptor
transitioning into a near four fold symmetry, while the AMPA receptor showed
smaller decoupling (U[, Uf, UY, \U, WYU). However, cysteine crosslinking studies by
Soblovesky and coworkers question the large decoupling seen in the AMPA receptors
(\\), as desensitization is observed even in the cross-linked non-decoupled receptor.

The smFRET measurements under desensitizing conditions showed
heterogeneity at the dimer-dimer interface at the amino-terminal domain and
minimal decoupling. This would be similar to the non-decoupled states seen with
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crosslinking (\\). Additionally, the smFRET data show that the large decoupled
agonist-binding domain structure seen in the cryo-EM structure accounts for a small
fraction of the receptors in the desensitized state. However, a large fraction of the
receptors show no or slight decoupling similar to what has been observed in the
AMPA receptors. Based on the smFRET measurements it can be concluded that
kainate and AMPA receptors exhibit largely similar trends in terms of structural
heterogeneity in the desensitized state with much smaller differences than was
previously thought.

SmFRET measurements characterizing the proximity of the agonist-binding
domain dimers in the presence of Cs+ show that the more decoupled states are
favored, and the energy barrier is lowered for transitions to more decoupled states.
This decrease in energy barrier is consistent with MD simulations that showed a
decrease in the work required to decouple the dimer interface in the absence of Na+
ions (WWf, W[U). The fact that the conformational states of the agonist-binding domain
are the same in both Na+ and Cs+ conditions suggest a conformational selection
mechanism. The occupancy of similar states is consistent with the fact that the X-ray
structures of the isolated agonist binding domain are similar under both Na+ and Cs+
conditions. The smFRET data adds to this prior knowledge by showing that the
occupancy of these states are shifted.
Importantly, similar distances are found between sites U]] when measured
using both LRET and smFRET. The comparison of these data indicate that the
receptor is in a similar conformational arrangement in either lipid bilayer or detergent
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solubilized and that a direct comparison can be made between the two techniques.
Unfortunately, LRET measurements were limited to the ATD due to functional
limitations of the receptor.

Conclusions
Using a combination of LRET and smFRET measurements we have
characterized the conformation and energy landscapes of the kainate receptor in the
apo, antagonist-bound, active, desensitized, and Na+-modulated states. These data
suggest a similar conformational heterogeneity as seen in the AMPA receptors. The
desensitized and resting states of the receptor are energetically altered in the presence
of Cs+, which drives the protein into a decoupled dimer state which in turn leads to
lower activation.
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Chapter 7: FRET Studies of the GluK2/GluK5 Heteromeric Receptor

This chapter is based upon research originally published in Biochimica et
Biophysica Acta- Biomembranes. Litwin, D. B., N. Paudyal, E. Carrillo, V. Berka, and V.
Jayaraman. The structural arrangement and dynamics of the heteromeric
GluKU/GluKd kainate receptor as determined by smFRET. Biochimica et Biophysica
Acta- Biomembranes. UVWX; DOI: WV.WVW]/j.bbamem.UVWX.Vd.VU\ © Elsevier B.V.

As discussed in chapter [, the majority of ionotropic glutamate receptor
models available are of the AMPA and NMDA subtype with only three available for
full-length homomeric GluKU kainate receptors, one in the antagonist-bound form
(Ud, UX) and two in the agonist-bound form exhibiting desensitized state (U], UX). The
structural data available for the homomeric kainate receptor has laid a foundation for
our understanding of the structural characteristics that give rise to the unique
function of kainate receptors.
The heteromeric GluKU/GluKd kainate receptor is known to be the most
abundant kainate receptor expressed in the brain (WX\). Therefore, identifying the
structural features that are unique to the GluKU/GluKd heteromer is crucial to design
therapeutically potential kainate receptor specific compounds. Yet, the only structural
models currently available for the heteromeric kainate receptor are of the isolated
amino-terminal domains (WUd). MD simulations on the homology model of isolated
agonist-binding domain dimer show that the heteromeric receptor has more
decoupled dimer interface relative to the homomeric receptors (WY[). Functionally the
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GluKU/GluKd heteromer has shown higher glutamate sensitivity (Yd, WX[-WX]) and a
faster rate of desensitization (tdes GluKT/KZ = ~\ ms) compared to the homomeric
receptor (tdes GluKT = d.Y ms) in the presence of sodium ions (WY[). These differences in
function leave no question that there are valuable structural characteristics of
heteromeric kainate receptors left to be resolved. The only advances in our
understanding of the structure of the GluKU/GluKd heteromer show that they localize
to the plasma membrane with a subunit stoichiometry of U:U and that the GluKU
amino-terminal domains likely mediate the amino-terminal domain dimer-dimer
interface (WU[, WUd).

FRET acts as a molecular ruler providing distances between the donor and
acceptor fluorophores attached to specific sites of a molecule, and when used at the
single molecule level allows for investigating the conformational landscape and
energetics of functionally-significant dynamics within molecules (W\[, Wdd-WdY, W]V,
WfV, WfY). For the single molecule FRET (smFRET) measurements, membrane
preparations of cells expressing the protein used with minimal purification, thus
providing insight into the proteins in a near native conformation (W\[, Wdd-WdY, W]V,
WfV, WfY). Here, we have used smFRET to address the specific arrangement of the
receptor, and to understand the conformational landscape of the heteromeric
receptor, specifically the conformational landscape across the dimer-dimer interface at
the amino-terminal domain, the dimer interface at the agonist-binding domain and at
the transmembrane segments. These sites were chosen as they are known to play
important roles in activation and desensitization in the homomeric kainate receptor
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and/or the closely related AMPA receptor (\\, W[\, WXf-WXX). Additionally, the sites at
the amino-terminal domain and agonist-binding domain are equivalent to those that
we used to study the homomeric receptors (UVV), thus a direct comparison of
differences between the conformational landscape of the heteromeric and homomeric
receptors can be made and correlated to differences in function.

Results and discussion
For smFRET measurements we modified the GluKU and GluKd receptors to
remove accessible cysteines as shown in Figure TI (modified constructs are referred to
as GluKU* and GluKd*). Additionally, we have introduced a twin strep tag on the
background of GluKd constructs. Since, GluKd subunits do not express as homomeric
receptors (WU[, WdW, UVW-UV\), performing the in situ pull down using streptavidin on
membrane preparations of HEK-UX\ cells co-expressing GluKU and GluKd subunits
allows for the specific attachment of GluKU/GluKd receptors and excludes the
attachment of GluKU homomeric receptors.
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Figure 21. Structural arrangement of the GluK2/GluK5 heteromeric receptor.
Extracellular amino-terminal domain (ATD) and agonist-binding domain (ABD)
represented as bilobed structures in domain swapping configuration. Accessible
cysteines modified to form cysless constructs for GluK5 and GluK2 subunits are shown
as red spheres. Transmembrane domain (TMD) consisting of four helices M1, M2, M3
and M4, are represented as cylindrical structure inside the membrane. A twin-strep
tag is attached to the C-terminus of GluK5 subunit shown in green.
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Arrangement of GluK2 and GluK5 subunit with the kainate receptor.
Given that the kainate receptor subunits are arranged as dimer of dimers, the
GluKU and GluKd subunits can be assembled in three possible configurations (Figure
TT). To determine the configuration(s) that the receptor occupies using smFRET, we
measured distances between sites U]] and U]] in the two GluKU subunits, and
equivalent sites UfU and UfU in the two GluKd subunits, within the GluKU/GluKd
heteromeric receptors. These sites were chosen based on homology models of the
GluKU/GluKd receptors generated which show that the distances between these sites
can be used to clearly differentiate between the possible configurations (Figure TW AC). The functionality of GluKU*-U]]/GluKd* and of GluKU*/GluKd*-UfU subunits
labeled with Alexa ddd and Alexa ][f fluorophores were established using whole cell
current recordings (Figure TY).
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Figure 22. Representation of the possible arrangments of the heteromeric
amino-terminal domains.
Possible configurations for amino-terminal domains of GluK2 and GluK5 subunits in
GluK2/GluK5 heterotetramer forming dimer of dimers.
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Figure 23. Homology models for heteromeric sites GluK2*-266 and GluK5*-272
with corresponding efficiency histograms.
(A) Full-length structure of the apo state GluK2/GluK5 heteromer (homology model
made from PDB 3KG2) with the GluK2 subunits shown in blue and the GluK5 subunits
shown in green. Alpha carbon sites at GluK2*-266 are shown as red spheres. (B-C) Top
down view of alpha carbon sites at GluK5*-272 and alpha carbon sites at GluK2*-266
with their corresponding distances. (D-E) smFRET data for GluK2*-266 sites; with two
representative smFRET efficiency traces for individual molecules shown in panel D
and cumulative smFRET efficiency traces with observed data (grey) overlaid on
denoised data (red) are shown in panel E. Gaussian fits shown in black, blue and
green, represents the smFRET efficiency states.
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Figure 24. Heteromeric FRET construct characterization.
Representative whole-cell recording for GluK2*-523/GluK5*, GluK2*/GluK5*-272,
GluK2*-266/GluK5*, GluK2*-479/GluK5*-471 and GluK2*/GluK5*-515.
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smFRET traces for constructs GluKU*-U]]/GluKd* exhibiting a single donor
and single acceptor photobleaching step with anticorrelation upon acceptor bleaching
were used for generating the smFRET efficiency traces for individual molecules
(representative trace shown in Figure TWD). The fractional occurrence in the smFRET
efficiency traces were then used to generate the smFRET efficiency histogram. The
cumulative histogram from smFRET efficiency traces from UY molecules, for GluKU*U]]/GluKd* is shown in (Figure TWE). The donor and acceptor traces were denoised
using wavelet based denoising and the denoised FRET histograms generated from
these are shown overlaid on the observed histogram (Figure TWE). The smFRET
histogram shows primarily two states with a FRET efficiency of V.fU and V.Y\,
corresponding to distances of [U Å and \X Å. These distances are close to the alpha
carbon distance between the U]] and U]] residues (values are shown in Table I) as
predicated when placing the GluKU subunits proximal to each other (Figure TTA).
Additionally, given that this distance is significantly shorter than the distance of ]f Å
expected in the configuration placing two GluKU subunits within the dimer as seen in
GluKU homomer (PDB dKUH), it can be concluded that the configuration with GluKU
(Figure TTB) within the peripheral position the dimer does not exist in the heteromer.
smFRET experiments for the GluKU*/GluKd*-UfU receptors on the other hand
showed no molecules with significant smFRET efficiency traces. W[Y molecules probed
exhibited one or multiple donor steps or one or multiple acceptor steps, but no
molecules showed FRET between the donor and the acceptor. Based on this
observation it can be concluded that no significant fraction of the GluKU/GluKd
heteromeric receptors exist in the configuration placing the GluKd subunits proximal
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Alpha carbon distance in
Apo state
Sites

GluK2*-266 -

Desensitized state

FRET

Å for homology models

FRET

Eff.*

Gaussian fit

Eff.*

Gaussian fit

5KUF

3KG2

5KUH

0.72

0.72 (+/- 0.03

0.83

0.84 (+/- 0.004

-

-

47

44

-

0.8

0.80 (+/- 0.003

0.56

0.56 (+/- 0.01)

0.69

0.68 (+/- 0.003)

0.83

0.83 (+/- 0.001)

37

39

57

0.84

0.93 (+/- 0.002)

-

34

38

34

38

GluK2*-266

GluK2*-479 GluK5*-471

0.9

GluK2*-523 -

0.90 (+/- 0.001

0.83

0.83 (+/- 0.005)

0.85

0.83 (+/- 0.008)

0.96

0.96 (+/- 0.002)

0.94

0.94 (+/- 0.002)

0.81

0.81 (+/- 0.003)

0.84

0.85 (+/- 0.01)

GluK2*-523

GluK5*-515 GluK5*-515

0.94

0.94 (+/- 0.002)

0.93

0.95 (+/- 0.003)

Table 1. Summary of smFRET efficiencies and distances calculated
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-

to each other (Figure TTC) and within a dimer (Figure TTB). Therefore, the
heteromeric receptor exists primarily in the configuration shown in Figure TTA. and
is consistent with the X-ray structure of the isolated amino-terminal domain of the
GluKU-GluKd heterotetramer (WUd).

Comparison of the conformational landscape of heteromeric to homomeric receptors at
dimer-dimer interface at the amino-terminal domain.
The smFRET data of GluKU*-U]]/GluKd* show two states with FRET
efficiencies of V.fU and V.Y\, while the smFRET data of homomeric GluKU receptors at
this site showed three states of FRET efficiencies V.]X, V.Y\ and V.XU (UVV). The most
probable state of V.Y\ is identical in both suggesting that the two receptors have a
similar conformational arrangement of the dimer-dimer interface at the aminoterminal domain for the main conformational state. The similarity in primary
conformation and lack of large-scale differences at the amino-terminal domain
between the homomeric and heteromeric receptors would be consistent with the
previous biochemical studies suggesting that the amino-terminal domain plays a
major role in assembly (WUd, UV[).

Conformational landscape of the agonist-binding domain.
To study the conformational dynamics at the dimer interface in the agonistbinding domain, we introduced cysteines at site [fX on GluKU* and [fW on GluKd*
(Figure TZA-B). These sites are ideal as the distance between these residues are
distinct within the dimer, relative to that across the dimers (Figure TZB). smFRET
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traces showing a single donor and single acceptor photobleaching step with
anticorrelation between the two were used to generate the FRET efficiency traces, and
U]-UY molecules were combined to generate the cumulative smFRET efficiency
histograms. The smFRET histograms in the apo state show two states with efficiencies
of V.Y and V.X (Figure TZD), corresponding to distances of [V Å and \d Å. These
distances are close to the alpha carbon distance between residues GluKU*-[fX and
GluKd*-[fW (values are shown in Table W) based on homology models when placing the
subunits as in configuration Figure TTA, further confirming that this is the primary
configuration for the heteromeric receptor. The smFRET histograms for the
glutamate-bound state, on the other hand, shows four states with FRET efficiencies of
V.d], V.]X, V.Y\ and V.X[ (Figure TZD). The lower FRET efficiency state V.d] with a
distance of [X Å corresponds well with the distance of dW Å observed in the
desensitized state structure of GluKU homomeric receptor (PDB dKUH) showing a
pseudo four-fold symmetry, suggesting that a fraction of the protein exists in the
conformation similar to this structure under desensitizing conditions. However, the
conformations with less decoupling at the dimer interface of the agonist-binding
domain also exist suggesting that complete decoupling as seen in the pseudo four-fold
symmetry is not essential for desensitization.
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Figure 25. Homology model for heteromeric sites GluK2*-479 and GluK5*-471
with corresponding efficiency histograms.
(A) Full-length structure of the apo state GluK2/Gluk5 heteromer (homology model
made from PDB 3KG2) with alpha carbon sites at GluK2*-479 (magenta spheres) and
GluK5*-471 (red spheres). (B) Top down view of alpha carbon sites at GluK2*-479
(magenta spheres) and at GluK5*-471 (red spheres) with their corresponding measured
distances at apo state (left panel) (homology model made from PDB 5KUH) and
desensitized state (right panel) (homology model made from PDB 5KUF) of
GluK2/GluK5 heteromer. (C-D) smFRET data for GluK2*-479 and GluK5*-471 sites at
the apo state (left panel) and the desensitized state (right panel). (C) Two
representative smFRET efficiency traces for individual molecules. (D) Cumulative
smFRET efficiency traces with observed data (grey) overlaid on denoised data (red).
Gaussian fits shown in black, blue and green, represents the smFRET efficiency states.
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Comparison of the conformational landscape of heteromeric to homomeric receptors at
the agonist-binding domain dimer interface.
The smFRET histograms of the heteromeric receptor in the apo state shows the
additional lower FRET state of V.Y, which is not observed in the smFRET histogram of
the homomeric GluKU receptor in the apo state. The apo state of the homomeric
GluKU receptor exists in a single conformation with a FRET efficiency of V.YX (UVV).
The existence of a more decoupled second conformation in the heteromeric receptor
is consistent with prior MD simulations with the isolated agonist-binding domain
where a shift of about W Å towards a more decoupled state was observed (WY[). The
smaller shift in the MD simulations versus that seen in the smFRET could be due to
the fact that the distances were measured closer to the dimer interface in the MD
simulations and not at the same site being studied in the smFRET measurements.
Additionally, the simulations were on the isolated domain and it is possible that the
changes are larger in the full-length receptor.
A favoring of the more decoupled state is also observed in the smFRET data for
the glutamate-bound homomeric (desensitized) state (UVV). While, the FRET
efficiencies of V.d], V.]X, V.Y\ and V.X[ in the glutamate-bound state for the
heteromeric receptors are similar to the FRET efficiencies of V.d[, V.]X, V.YU and V.X\
seen in the homomeric GluKU receptors, the fractional occupancy is higher for the
more decoupled state in the heteromeric receptors relative to the homomeric
receptors. This shift towards the more decoupled state would be consistent with the
faster desensitization rates observed in the heteromeric receptors relative to the
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homomeric receptors (tdes GluKT/KZ = ~\ ms, tdes GluKT = d.Y ms) in the presence of
sodium ions (WY[).

Conformational landscape at the transmembrane segments.
In order to study the conformational dynamics at the transmembrane
segments we introduced cysteines at site dU\ on GluKU* and dWd on GluKd* (Figure
T[, T]). These sites are positioned at the top of the first transmembrane segment,
which makes them ideal to measure the distance across the pore axis at
complementary sites. smFRET traces showing a single donor and single acceptor
photobleaching step with anticorrelation between the two were used to generate the
FRET efficiency traces, and Uf-\W molecules were combined to generate the cumulative
smFRET efficiency histograms. The smFRET histograms for GluKU*-dU\ in the apo
state show two states with efficiencies of V.Y\ and V.X] (Figure T[D) and correspond
to distances of \X and \V Å. These distances are close to the alpha carbon distance of
residue dU\ - dU\ in the two GluKU subunits obtained from the apo state homology
model with the channel being in a closed state (Figure T[ A-B, Table I). The higher
FRET efficiency peak centered at V.X] that corresponds to a distance of \V Å possibly
represents a tighter packing at the transmembrane segment. The smFRET histograms
for GluKU*-dU\ in the glutamate-bound state show two peaks with efficiencies of V.Yd
and V.X[ (Figure T[D), corresponding to distances of \Y and \U Å. These efficiencies
are similar to what is found under apo conditions at this site; however, there is a
significant shift in occupancy toward the high FRET state, suggesting the more tightly
packed transmembrane conformation is favored in the desensitized state.
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Figure 26. Homology model for heteromeric sites GluK2*523 and GluK5* with
corresponding efficiency histograms.
(A) Full-length structure of the apo state GluK2/Gluk5 heteromer (homology model
made from PDB 3KG2) with alpha carbon sites at GluK2*-523 (red spheres). (B) Top
down view of the apo state (left panel) (homology model made from PDB 3KG2) and
the desensitized state (right panel) (homology model made from PDB 5KUF) of
GluK2/GluK5 heteromer displaying alpha carbon sites at GluK2*-523 (red spheres)
with their corresponding measured distances. (C-D) smFRET data for GluK5*-523 sites
at the apo condition (left panel) and the desensitized state (right panel). (C) Two
representative smFRET efficiency traces for individual molecules. (D) Cumulative
smFRET efficiency traces with observed data (grey) overlaid on denoised data (red).
Gaussian fits shown in black, blue and green, represents the smFRET efficiency states.
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The smFRET histograms for GluKd*-dWd in the apo state show two states with
efficiencies of V.YW and V.X[ (Figure T]D) and correspond to distances of [V and \U,
and in the glutamate-bound state show two peaks with efficiencies of V.Y[ and V.X\
(Figure T]D), corresponding to distances of \X Å and \\ Å. The smFRET data from
site GluKd*-dWd are similar to site GluKU*-dU\ in the glutamate-bound state showing
that at this site the protein exhibits a four-fold symmetry in both the apo and
glutamate-bound state.
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Figure 27. Homology model for heteromeric sites GluK2* and GluK5*-515 with
corresponding efficiency histograms.
(A) Full-length structure of apo state GluK2/Gluk5 heteromer (homology model made
from PDB 3KG2) with alpha carbon sites at GluK5*-515 (red spheres). (B) Top down
view of the apo state (left panel) (homology model made from PDB 3KG2) and the
desensitized state (right panel) (homology model made from PDB 5KUF) of
GluK2/GluK5 heteromer displaying alpha carbon sites at GluK5*-515 (red spheres) with
their corresponding measured distances. (C-D) smFRET data for GluK5*-515 sites at
apo condition (left panel) and desensitized state (right panel). (C) Two representative
smFRET efficiency traces for individual molecules. (D) Cumulative smFRET efficiency
traces with observed data (grey) overlaid on denoised data (red). Gaussian fits shown
in black, blue and green, represents the smFRET efficiency states.
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Conclusions
There are a plethora of X-ray crystallography and cryo-EM structural models
available for the AMPA and NMDA classes of iGluR including both isolated aminoterminal and agonist-binding domains, and also the full-length receptors. However,
only three structural models have been produced for the full-length homomeric GluKU
receptor type. Currently, there are no structures of the full-length GluKU/GluKd
heteromeric receptor. Using smFRET investigations, we show that GluKU/GluKd
heteromeric receptor assemble in one configuration with the GluKU sites occupying
proximal positions across the dimer-dimer interface at the amino-terminal domains of
the receptor. Additionally, we show that the spread of conformational states is not
significantly different between the homomeric and heteromeric receptors at the
dimer-dimer interface at the amino-terminal domain suggesting that the primary role
of this domain is in assembly. The agonist-binding domain, on the other hand, shows
more decoupling and a higher occupancy of the decoupled state at the dimer interface
in both the apo and glutamate-bound states of the heteromeric receptors relative to
what is observed in the homomeric receptors. Given the prior studies that have shown
the decoupling of the dimer interface at the agonist-binding domain as being the
primary conformational change driving desensitization, the increase in decoupling at
this interface in the agonist binding domain of the heteromeric receptor ties back to
the functional studies that show a faster desensitization rate in the heteromeric
receptor relative to the homomeric receptors. The smFRET studies also show that the
GluKU/GluKd heteromeric receptors loses its two-fold symmetry and exhibits four-
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fold symmetry at the start of the first transmembrane segment in both the apo and the
glutamate-bound forms of the receptors.
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Chapter 8: The Effects of Neto Modulation on Kainate Receptor Structure

Parts of this chapter are based upon research originally published in
Biophysical Journal. Prakash, P., D.B. Litwin, H. Liang, J. Hancock, V. Jayaraman and
A. Gorfe. Dynamics of membrane-bound GWUV-KRAS from simulations and singlemolecule FRET in native nanodiscs. Biophysical Journal. UVWX; WW](U): WfX-WY\ ©
Biophysical Society.

As discussed in chapter \, there are significant changes in the kinetics of KAR
gating when co-expressed with Neto proteins. There is currently no structural data for
Neto proteins or KARs as affected by Neto proteins. In order to characterize the
structural effects of Neto modulation on KARs, LRET and cryo-EM experiments were
conducted on the homomeric GluKU KAR co-expressed with NetoU.
The architecture of the KAR positions the amino-terminal on the extracellular
side of the plasma membrane. Neto proteins are also in this arrangement. Given that
the two proteins are positioned with intercellular C-termini, it is not possible to create
a tandem construct for structural studies, as has been done with AMPARs and
stargazin. This creates difficulty in studying the structure of this complex using
smFRET and cryo-EM.
LRET, however, provides an excellent platform for circumventing this issue.
LRET experiments allow for measurements to be made on non-purified samples, such
as HEK cells expressing the protein of interest as seen in previous chapters. Therefore,
the amino-terminal domain constructs which retained function were ideal candidates
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to begin characterizing the structural influences of Neto proteins and as previously
discussed, there is evidence that Neto proteins interact with the ATDs of the KAR.
Given that loss of function was observed for KAR mutants designed for measurements
in the ABD layer, purification strategies capable of maintaining the KAR-Neto
interactions were further investigated.
While detergents like digitonin have been used in structural studies of protein
complexes, there have been difficulties in obtaining quality samples of KARs purified
using these methods. Therefore, solubilizing agents capable of forming nanodiscs
including lipid bilayer were considered for testing. Currently, the only technologies
shown to be capable of maintaining protein complexes in nanodiscs are membrane
scaffold protein (MSP) and styrene maleic acid copolymers (SMA). Since SMA does
not require pre-solubilization in detergents, a purification strategy utilizing SMA was
optimized for use in cryo-EM studies of the KAR-NetoU complex. Preliminary LRET
and cryo-EM imaging experiments will be discussed in this chapter.

Amino-terminal domain LRET studies of the KAR-Neto complex
As discussed in chapter \, several studies have highlighted the role of the ATD
in the trafficking of Neto proteins. While the specific mechanisms involved in the
KAR-Neto interaction are not currently known, these data hint that there could be
important interactions between the KAR ATD and Neto proteins. For this reason,
LRET experiments were conducted using construct GluKU*UUC and GluKU*U]]C, and
GluKU*UUC and GluKU*U]]C co-expressed with NetoU. These constructs are design to
monitor the distance within ATD dimer pairs and between ATD dimer pairs
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respectively. As previously mentioned, LRET experiments were limited to the ATD due
to loss of function with ABD constructs.
In order to characterize the effect of Neto modulation on the KAR ABD dimers,
LRET measurements were made on construct GluKU*UUC. LRET decay plots for
construct GluKU*UUC co-expressed with NetoU are shown in Figure T^. Under apo
conditions and without NetoU present, the LRET lifetime obtained is f\W µs. This
corresponds to a distance of [[ ± V.Ud Å. Under glutamate-bound conditions without
NetoU, the lifetime obtained was fWY µs, which corresponds to a distance of [[ ± V.]W
Å. Under apo conditions and with NetoU co-expressed, the lifetime obtained was dYV
µs which corresponds to a distance of [W ± W.W Å. Under glutamate-bound conditions
with NetoU co-expressed, the lifetime was df\ µs, which corresponds to a distance of
[W ± V.YY Å. These data show that there is slight decrease in distance at site UUC when
GluKU is expressed with NetoU.
In order to characterize the effects of Neto modulation on the distance
between ATD dimer pairs, LRET measurements were conducted on construct
GluKU*U]]C shown in Figure ]. The fluorescent decay plots for construct
GluKU*U]]C are shown in Figure Ta. Under apo conditions without NetoU coexpressed the lifetime was ]WX µs which corresponds to a distance of [U ± V.[f Å.
Under glutamate-bound conditions without NetoU co-expression the lifetime was d]X
µs which corresponds to a distance of [W ± V.\X Å. Under apo conditions with NetoU
co-expressed the lifetime was WVV\ µs, which corresponds to a distance of dV ± V.XW Å.
Under glutamate-bound conditions NetoU co-expression the lifetime was XXV µs,
which corresponds to a distance of dV ± W.\ Å. These data indicate that when GluKU is
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co-transfected with NetoU, the ATD dimer pairs are separated by a greater distance
than when expressed alone.
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(blue). Measurements were made using terbium chelate (donor) and fluorescein
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Figure 28. LRET data for amino-terminal domain construct GluK2*22C.
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Figure 29. LRET data for the amino-terminal domain construct GluK2*266C.
(a) Acceptor fluorophore decay plots under apo conditons for GluK2*266C (black) and
in the presence of Neto2 (blue). (b) Acceptor fluorophore decay plots under
glutamate-bound conditions for GluK2*266C (black) and in the presence of Neto2
(blue). Measurements were made using terbium chelate (donor) and fluorescein
(acceptor).
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Agonist-binding domain LRET studies of the KAR-Neto complex
To measure the effect of Neto co-expression on the ABD dimer proximity,
construct GluKU*[dY was characterized using LRET, shown in Figure Wb. Fluorescent
decay plots are presented in Figure WI. Under all conditions, florescent decay plots
which fit to double exponential decay were produced. Under apo conditions without
NetoU co-expressed, lifetimes of ]]X and WW[Y µs were obtained, which corresponds to
distances of [\ ± V.XW Å and d[ ± W.] Å. Under glutamate-bound conditions without
NetoU co-expression the lifetimes obtained were dUX and WVdW µs, which corresponds
to distances of [V ± V.[W Å and dW ± W.[f Å. These distances are different than those
obtained previously using cryo-EM; however, the faster lifetime corresponding to [V Å
fits well in the cryo-EM models, while the longer lifetime corresponding to dW Å is
significantly shorter than expected, as seen in Figure Wb. It is also important to note
that at this site it is not possible to determine if the longer lifetime has contribution
from the diagonal distance between sites being measured (see Figure Wb).
Under apo conditions with NetoU co-expressed the lifetimes were [fX and WVW]
µs, which corresponds to distances of \X ± V.d\ Å and dV ± W.\ Å, Figure WIb. Under
glutamate-bound conditions with NetoU co-expression the lifetimes were dV\ and
WVdd µs, which corresponds to distances of [V ± V.\U Å and dW ± W.U Å. These data show
a decrease in distance between ABD dimer pairs when co-expressed with NetoU. This
indicates that NetoU induces a tighter packing of the ABD layer and likely explains the
gain in function by conferring additional support between the dimer pairs.
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Figure 30. Structural model of a homomeric kainate receptor showing site 458.
(Upper panel) top-down view of homomeric GluK2 with site 458 shown as black
spheres. (Lower panel) geometry of distances between site 458.
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a

b

Figure 31. Agonist-binding domain LRET acceptor decay plots with double
exponential lifetime fits.
(A) Construct GluK2*458C measured under apo conditions (black) and glutamatebound conditions (red). (B) Construct GluK2*458C co-expressed with Neto2 measured
under apo conditions (black) and glutamate-bound conditions (red).
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Cryo-electron microscopy studies of the KAR-Neto complex

Styrene maleic acid solubilization
As previously discussed, there are experimental difficulties in studying the
KAR-Neto complex which result from the inability to create a tandem construct for
characterization. The concern results from the inability to ensure that all of the KARs
are paired with Neto proteins. When using detergent to solubilize proteins, the
detergent molecules typically displace the lipids and proteins interacting with the
receptor at the membrane. This problem can be overcome through the use of styrene
maleic acid (SMA) to solubilize the complex. Previous studies have shown that
receptors solubilized in SMA not only retain a disk of lipids surrounding the protein,
they retain the native lipids normally associated with the proteins (UVd, UV]).

Solubilization of KRAS
There are a number of structural models and molecular dynamic simulations
published for KRAS proteins; however, resolving functionally relevant conformational
states has been limited by their functional requirement for a bilayer. Therefore, the
data available for KRAS proteins makes it an ideal protein to validate and optimize a
protocol for SMA solubilization. In order to optimize a SMA purification protocol for
use in smFRET and cryo-EM, experiments characterizing the membrane protein KRAS
using smFRET were performed.
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The mammalian RAS family of proteins includes the isoforms NRAS, HRAS,
and KRAS. RAS proteins are GTP signaling proteins tethered to the inner side of the
plasma membrane. After binding GTP, RAS proteins transduce extracellular signals to
the nucleus through signaling cascades. KRAS has become of particular interest for its
potential in treating cancer due to studies showing that mutations altering its GTP
activity lead to a variety of cancers (UVf, UVY).
The structure of KRAS proteins is composed of a bi-lobed catalytic domain and
a flexible C-terminal hypervariable region containing a polybasic and farnesylated
lipid anchor. It is known that the KRAS catalytic domain can also interact with anionic
model membranes in three orientation states (OS). OSW involves interactions with ahelices \-d on lobe U. OSU involves interactions with b-strands W-\ on lobe W, and OSV
in which a-helices are perpendicular to the membrane. The OSW and OSU
conformations show different accessibility to the b-stand loops critical for
coordination with downstream signaling proteins, which suggests the KRAS signaling
could be modulated by membrane reorientation (UVX, UWV). However, currently only
inferences can be made from MD simulations and indirect spectroscopic techniques in
simple model membranes (UVX-UWU).
In these studies, we characterize the dynamic interactions between the
catalytic domain of KRAS and membrane lipids using a combination of atomistic MD
simulation and single-molecule fluorescence resonance energy transfer (smFRET).
Given the importance of the lipid membrane to KRAS structure, these experiments
were conducted with KRAS solubilized in styrene maleic acid nanodiscs.
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MD simulations were run and the distance between residue W\U on lobe U of the
catalytic domain and residue WY\ on the C-terminal were analyzed. The MD
simulations yielded results showing three dominant KRAS orientations with distances
of WX, \\ and [X Å between sites W\U and WY\, corroborating the \ state model including
OSW, OSU and OSV. However, the short timescales of the MD simulations limited the
number of transitions between different orientations. Therefore, smFRET
measurements were made to help resolve the frequency of transitions between the
different orientations. The smFRET efficiency histogram for GWUV-KRAS is shown in
Figure WT. Efficiency peaks were found centered at V.[V, V.f[, and V.X[. These FRET
efficiencies correspond to distances of [X, \X, and UX Å, which are very similar
distribution to the distances obtained with MD simulations. These results indicate
that the SMA purification strategy is sufficient to isolate the KRAS protein into
nanodiscs suitable for use in biophysical characterization. These results showed
promise in utilizing SMA for purification of the KAR-Neto complex, and that process
was investigated further.
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A

Figure 32. Representative trace and efficiency histogram for KRAS FRET
construct.
(A) FRET efficiency (EA) histogram fitted to three Gaussians, indicating three distinct
conformational states, with the high FRET state in blue, mid-FRET state in green, and
low FRET state in red. A representative EA trajectory indicating fast transitions
between states is shown as an inset, with the observed signal in red and state
transitions highlighted in black.
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Purification and imaging of the GluK2-Neto2 complex
Characterizing the structural arrangement and molecular interactions between
GluKU and NetoU would be best accomplished using cryo-EM imaging. There are now
several molecular models for the AMPA receptor in complex with its auxiliary proteins
resolved using cryo-EM, but no structural data is available for the KAR-Neto complex.
Therefore, the purification strategy optimized for the KRAS protein was adopted for
use with the KAR-Neto complex.
Initially, the KAR-Neto complex was expressed and purified using HEKUX\T
cells; however, the yields obtained from this expression system were inadequate for
cryo-EM imaging. Therefore, the insert containing the GluKU and NetoU constructs
were separately cloned into pFastBacW vectors to be used in the generation of
baculovirus. The baculoviruses generated were then used to co-transfect SFX insect
cells in order to produce high quantities of the GluKU-NetoU complex.
The SMA purification strategy optimized for the KRAS protein was then
adapted to a double purification scheme. For affinity chromatography purposes, the
GluKU construct included a hexa-histidine tag and the NetoU construct included a
FLAG tag. After SMA solubilization, the SFX cell lysates were applied to a Ni-NTA
resin and followed by elution using imidazole. Next the eluate was applied to a antiFLAG resin, washed and eluted using \X FLAG peptide. Both GluKU and NetoU were
clearly detected in the double purified eluate on western blots and ran as a single band
on a native page gel, see Figure WW.
The samples obtained following the double FLAG and His purification were
then imaged on a Technai G2 Polara cryo-electron microscope. The microscopy
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resulted in successful imaging of the receptor; example micrograph shown in Figure
WY. The receptors appear as tetrameric Y-shaped molecules, similar to what has
previously been described.
While these initial micrographs were promising, there were difficulties in
producing a signal oligomeric species with the purification protocol. The eluate
obtained from purification likely contains a mixture of various oligomeric states of the
complex. This is commonplace when purifying oligomers for structural imaging and
gel filtration chromatography is the traditional method for separating the different
oligomeric species. The yield obtained from the double purification was typically in
the V.W-V.[ mg/ml range. However, the yield following gel filtration chromatography
dropped to between V.VVd-V.VW mg/ml. The UV chromatograph also showed that the
majority of the protein was either retained in the column or exited in the void volume
as aggregate. Therefore, additional work must be done refining the purification
strategy to obtain samples that are homogenous enough to move forward with image
analysis.
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HIS/FLAG double purified fraction

SDS-PAGE | α-HIS IB

| GluK2

SDS-PAGE | α-FLAG IB | Neto2

BN-PAGE | silver stain | Single band

Figure 33. Representative SDS and native PAGE gel imaging.
Representative SDS-page imaging using anti-GluK2 and anti-Neto2 antibodies.
Representative blue native page gel imaging using silver stain.
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a

b

Figure 34. Representative cryo-EM micrograph.
(a) Representative cryo-electron micrograph of the GluK2-Neto2 purified fraction on a
holey carbon grid. (b) Enlarged area from the micrograph showing the KAR-Neto2
complex.
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Discussion
The LRET experiments presented show that Neto2 modulation affects the
conformational arrangement of the ABD layer. Neto2 co-expression produced
measurements with shorter distances between dimer pairs, indicating the ABDs are in
a more tightly packed arrangement. These are intriguing data showing that, not
surprisingly, KAR kinetics are being modulated by altering the conformation and
therefore the dimer interface interactions. Unfortunately, the mutations required for
LRET experiments nullified the function of the receptor when positioned to measure
within the ABD layer. Therefore, it could not be determined that the structural effects
we found are relevant to the true function involved in Neto2 modulation or if they
arise from misfolding introduced through the mutated residues. These limitations are
not a concern for investigations utilizing smFRET and these experiments will be
performed.
The strategy for purification of the KAR-Neto2 complex has produced
promising results; however, the problems in obtaining high-yield samples following
gel filtration chromatography have limited the progress made imaging the complex.
These studies are currently being continued through a collaborative effort with
Columbia University and preliminary results look promising.
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Chapter 9: Conclusions and Future Directions
The work presented herein contributes to our understanding of the structure
function relationship in kainate receptors. Prior to these studies, there were no data
characterizing the structural dynamics of either full length homomeric or heteromeric
kainate receptors. Here we used a combination of LRET and smFRET to reveal the
underlying structural dynamics that drive kainate receptor function and modulation
by ions and auxiliary proteins. The data we obtained are consistent with many of the
previous studies regarding kainate receptor gating, ion modulation and auxiliary
protein modulation. However, our findings regarding the dynamics of the glutamatebound state refine our understanding iGluR gating.
These studies show that unlike what is seen in the AMPA receptor, the ATDs of
the homomeric and heteromeric KAR maintain relatively low dynamics and remain in
close proximity throughout the gating cycle. We show that the ABDs retain a tightly
coupled dimer interface under apo conditions which agrees with previous structural
studies. We show for the first time in kainate receptors that the ABDs remain tightly
coupled during the active state and that separation at the dimer interface is the
initiating step for entry into the desensitized state. Interestingly, the glutamate-bound
data confirm the previously-hypothesized existence of multiple receptor states. In
addition, the data show that the higher FRET states are favored indicating that the
extreme decoupling seen in current KAR models is likely an artifact of the purification
process for cryo-EM. This finding stands in contrast to our current understanding of
KAR desensitization, yet is in agreement with a previous study suggesting that
decoupling at the ABD dimer interface is not required for gating.
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The heteromeric studies show that the ATDs occupy similar distances and
dynamics between homomeric and heteromeric KARs and are in agreement with
previous structural studies. The ABDs, however, show significant differences between
homomeric and heteromeric receptors with the heteromer showing decoupling in
both the apo and glutamate-bound states. The decoupling found in the heteromeric
glutamate-bound state shows less preference for the more coupled interface as
compared to the homomeric receptor. These structural differences are in agreement
with functional differences seen between homomeric and heteromeric KARs, showing
more rapid entry into the desensitized state in heteromers.
The investigations into the structural effects of Neto modulation show that,
similar to what is found in the AMPARs, the auxiliary protein is reorienting the ABD
dimer pairs into a more compact arrangement. A reorientation of this nature would
affect the stability of the ABD dimer interface and explains the gain in function
resulting from Neto co-expression. Collectively these experiments highlight the
importance of the ABD dimer interface in receptor function.
As discussed and examined throughout this dissertation, the interface within
the ABD dimers is critical for receptor function. The current model of iGluR gating
puts the decoupling of the ABD dimer interface as the major driving force regulating
receptor kinetics. While the ABD interface is certainly the most important site
regulating gating kinetics, the decoupling previously found in KAR models is not
corroborated by our data nor by structural models of the AMPA receptor co-expressed
with auxiliary proteins. In both the homomeric and heteromeric studies, distances
corresponding to current structural models are found but represent the least favored
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state. This finding highlights the importance of characterizing the dynamics of
proteins under conditions more similar to what the receptor experiences in its native
environment. While imaging the receptor under crystalized or vitrified conditions is
critical for understanding the tertiary and quaternary arrangement of the proteins, it is
insufficient for accurately resolving structural dynamics and the conformational
arrangements involved with function.
Given the difficulties in obtaining high resolution KAR models and the
inherently dynamic nature of iGluRs, it seems clear that a combination of static and
dynamic experimentation is required for a comprehensive understanding of
mechanisms underlying the processes of activation and desensitization. The work
presented in this dissertation advances our understanding of KARs by combining
previously resolved structural models with physiologically relevant conformational
states and the dynamics of the full-length homomeric and heteromeric KAR. The
combination of these data makes it possible to more accurately model receptor
behavior using MD simulations and identify topological chemistries ideal to
discriminate between iGluR subtypes and KAR subunit compositions. The advances in
knowledge made through these studies bring the possibility of introducing novel
therapeutic drugs targeting iGluRs closer to reality.
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Future directions
While these data progress our understanding of the structure/function
relationship in KARs, significant work remains to be done. KARs have consistently
proven to be difficult receptors to work with in regard to advancing our understanding
of their molecular structure and mechanisms. However, our laboratory is well
positioned to unite the most cutting-edge structural dynamic experimentation with
static models to resolve these difficult questions.

Further investigations into the agonist-binding domain
The experiments performed here on the ABD identify the one-dimensional
changes in distance relevant to receptor function in homomeric and heteromeric
KARs. In the homomeric receptor, we were limited to measurements being made
across the dimer interface near site [fX due to the convoluting effects of having the
labeling site on all four subunits. While these measurements are critical for
understanding the dynamics at this interface, it cannot resolve the \-dimensional
movements of this domain in homomeric KARs.
The heteromeric receptor provides a platform in which a series of onedimensional measurements made from different positions within the ABD and
between the ABD and ATDs can be made. While only measurements complementary
to the homomeric site have been made thus far, additional points of measurement are
not restricted as in the homomeric receptor. Further studies performed on additional
sites within the ABD, between the ABD and the ATD, and measurements made
between the ABD and lipids would integrate the \-dimensional movements within the
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protein complex, providing a complete picture of the dynamic landscape to be used as
constraints in MD simulations.

Neto interactions at the amino-terminal domain
The KAR amino-terminal domain has received the least attention of all the
domains. As previously discussed, there are no allosteric regulatory effects found in
the ATD and very little dynamics are shown. Our data align with previous studies
identifying the ATD’s involvement in Neto trafficking, which is significant for receptor
function. Currently only LRET studies have shown that Neto co-expression
significantly alters the conformational arrangement of the ATDs. Further experiments
utilizing smFRET to characterize the effect of Neto proteins on the ATD should be
performed. smFRET measurements made between ATD dimers and within the ATD
dimer pairs would verify the altered conformation observed using LRET. Additionally,
smFRET measurements made between the ATDs and different CUB domains within
the Neto proteins could be used to triangulate the position of Neto proteins relative to
the receptor; similar to what our laboratory has previously done with the AMPAstargazin complex.

A closer look at the transmembrane domain
Of the ordered domains of KARs, the transmembrane domain has been most
difficult to study due to experimental limitations. In the homomeric KAR it is not
possible to make LRET or smFRET measurements in this region due to its small
radius. However, as seen in this dissertation, the heteromer allows for measurements
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to be made in this domain. Measurements characterizing the effect of Neto
modulation would be of great value given that studies have shown that residues just
above the transmembrane helices are critical for Neto modulation.

The carboxyl-terminal domain
The CTD remains the most mysterious region of KARs due to their intrinsically
disordered nature. While it is unlikely that detailed crystallography or cryo-EM
models will resolve this region, smFRET could provide detailed insight into this
question. Fluorescent proteins have already been used in FRET experiments on CTD
position and smFRET with organic fluorophores would increase the resolution
significantly. Experiments measuring the dynamic effects of calmodulin and many
other intracellular signaling proteins binding to the CTD would shed light on the
structure-function relationship of this domain for the first time.

Neto proteins and modulation
We have shown that Neto proteins affect the orientation of the ABD and ATD
using LRET. Yet the mechanisms mediating their interaction, their sites of interaction
and the conformational arrangement of the Neto proteins remain in question.
Fortunately, there are a number of structural studies performed on CUB domaincontaining proteins homologous to Neto proteins. Given that we have structural
insight into CUB domains, and the tertiary structure of those domains is highly
conserved, these questions can and should be addressed using smFRET. smFRET
measurements made within and between the CUB domains when bound to the KAR
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would resolve the structural arrangement of Neto proteins. Additional measurements
made between the Neto protein and the KAR ATD and ABD would reveal the
architecture of the KAR-Neto complex. Importantly, these data would provide a
complementary view of the complex to be compared to the cryo-EM structure of the
complex when it becomes available.

New technologies for the study of membrane protein complexes
Cell signaling is one of the most important physiological functions in biology.
Given that signaling involves transducing a signal across a membrane, it is no surprise
that the majority of proteins involved in signaling cascades are membrane proteins.
Difficulties in studying membrane proteins arise from their transmembrane
architecture. Solubilizing membrane proteins for studies requires the use of
amphipathic molecules to bind their hydrophobic TM regions. Traditionally
detergents are used for solubilization; however, the nature of detergent and the
concentration used needs to be precisely optimized for success.
In recent years, membrane scaffold protein (MSP) and SMA copolymers have
been used to more efficiently solubilize membrane proteins. MSPs are advantageous
in that they allow for relatively precise control of the nanodisc size obtained; however,
they typically require prior solubilization into detergent. SMA, on the other hand,
allows for the direct solubilization of membrane proteins from native membranes.
This retains the native lipid environment and keeps the receptor associated with other
membrane proteins. Structures have been published using SMA solubilized samples
and have shown the utility of SMA while removing the need for time consuming
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detergent screening. Given the success of previous studies and our own SMA
purification, it seems that SMA has a bright future in structural biology.
More recently, developments in fluorophore and microscope technology have
increased the power of smFRET measurements to operate with four fluorescent
molecules, termed four-color FRET. This is groundbreaking technology in that it
converts the single dimensional measurement obtained in traditional FRET
measurements into multidimensional measurements. Experiments utilizing four color
FRET are able to quantitate the allosteric motions involved in complex protein
complexes in single measurements. iGluRs serve as a perfect subject for four color
FRET and, if used in combination with the ever-increasing power of MD simulations,
will revolutionize our view into the dynamics of the molecular world.

Final thoughts
Kainate receptors are fascinating and yet underappreciated proteins which,
along with other ionotropic receptors, have been instrumental in the evolution of
cognition in vertebrate species. The work presented in this dissertation has increased
our understanding of the structure-function relationship of kainate receptors, yet
much remains to be discovered. However, as computational technology and scientific
techniques continue to evolve, the mysterious link between synaptic transmission,
neural oscillation patterns, and cognition will be revealed.
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Appendix: Materials and Methods
Homomeric Studies
Parts of this section are based upon research originally published in Scientific
Reports. Litwin, D. B., E. Carrillo, S. A. Shaikh, V. Berka, and V. Jayaraman. The
structural arrangement at intersubunit interfaces in homomeric kainate receptors.
Scientific Reports. UVWX; X(W):]X]X © Springer Nature Publishing AG.

Generation of FRET mutants
The R. norvegicus GluKUEM construct (U], UX) was kindly provided by Dr. Mark
Mayer and retained the native glutamine at site dXV. The coding sequence for GluKU
was PCR amplified and inserted into pcDNA\.W. Mutations were introduced using
standard PCR-based mutagenesis methods. To create the background construct
GluKU*, non-disulfide-bonded cysteines at sites CXW, CWXX, C[\U, were mutated to
serines. On this background two constructs were made; one with SU]] mutated to
cysteine and one with A[fX mutated to cysteine. A third construct was made in which
both A[fXC and Dff]K mutations were introduced.

Electrophysiology
Mutant HEK UX\T cells were transfected using jetPRIME PolyPlus (wt-GluKU,
GluKU*SU]]C, and GluKU*A[fXC) or lipofectamine UVVV Invitrogen (GluKU*A[fXCDff]K), and were, in both conditions, co-transfected with GFP at a microgram ratio of
\:W per WV ml of media. After [-] h of incubation, cells were re-plated (\V mm dishes)
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at low density. Cells were labeled in dish with [VV nM of donor fluorophore Alexa ddd
maleimide (ThermoFisher) and [VV nM of acceptor fluorophore Alexa ][f maleimide
(ThermoFisher) in U mL extracellular buffer pH f.[ (WdV mM NaCl, W.Y mM MgClU, W
mM CaClU, \ mM KCl, WV mM glucose, and WV mM HEPES). Whole cell patch clamp
recordings were performed U[-[Y h after transfection, using fire-polished borosilicate
glass (Sutter instruments) pipettes with \-d mΩ resistance, filled with internal
solution: WWV mM CsF, \V mM CsCl, [ mM NaCl, V.d mM CaClU, WV mM HEPES, and d
mM EGTA (adjusted to pH f.[ with CsOH). The external solutions containing WdV mM
NaCl or CsCl, U.Y mM KCl, W.Y mM CaClU, W.V mM MgClU, and WV mM HEPES (adjusted
to pH f.[ with NaOH or CsOH) were (without and with WV mM glutamate) applied to
lifted cells using a stepper motor system (SF-ffB; Warner Instruments) with triple
barrel tubing. Recordings were performed using an Axopatch UVVB amplifier
(Molecular Devices) at −]V mV hold potential, acquired at WV kHz using pCLAMPWV
software (Molecular Devices), and filtered online at d kHz.

LRET sample preparation
HEK293T cells were transiently transfected according to JetPrime protocol at 10 µg per
10 cm plate and maintained in DMEM. For LRET measurements, cells were transfected
with a GluK2 construct alone. Cells were collected and washed three times using
extracellular buffer containing 160 mM NaCl, 1.8 mM MgCl2, 1 mM CaCl2, 3 mM KCl,
10 mM glucose, and 10 mM HEPES (pH 7.4). The washed HEK cells were then labeled
with 400 nM donor and 100 nM acceptor fluorophores in 3 ml extracellular buffer,
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rotating at room temperature in the dark for 1 hr. The donor fluorophore was terbium
chelate (Invitrogen), and the acceptor fluorophore was fluorescein maleimide
(Thermo Fisher Scientific) for cysteine mutants. After labeling, cells were washed and
resuspended in 2 ml extracellular buffer and used for LRET measurements.
Extracellular buffer used in Cs+ substitution experiments contained 150mM CsCl in
place of NaCl.

LRET data collection
A cuvette-based system consisting of a fluorescence lifetime instrument (EasyLife
L;Hoiba) and analysis software (Fluorescan 5.5; Optical building blocks) was used for
LRET measurements. All samples were excited at 337 nm. Emission was detected at
545 nm for donor-only samples, at 515 nm for fluorescein-labeled samples. LRET
measurements were taken in triplicate for a given condition followed by scans after
Factor Xa protease cleavage to quantitate the samples’ background signals without the
labeled receptors’ contribution to the signal. Fluorescent decay plots obtained for
given conditions and the background for that condition were then plotted in Origin
and averaged, and the background was subtracted from the full signal. Following
background subtraction, the resulting decay plots were fit to double exponential decay
functions thereby quantitating the decay lifetime of the acceptor fluorophore. Error in
the distance estimates was then calculated by propagating the errors in the donor and
acceptor lifetimes using the Error Propagation Calculator developed by Thomas Huber
in the Physics Department of Gustavus Adolphus College. Lifetimes were quantitated
for samples labeled with only the donor (tD) and samples labeled with both donor and
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acceptor (tDA), to be used to calculate the distance between the fluorophores using the
Forster equation:
𝑹 = 𝑹𝟎 (

t𝑫𝑨
𝟏
) ;𝟔
t𝑫 − t𝑫𝑨

where R is the distance between donor and acceptor fluorophore, R0 is the distance
yielding half-maximal energy transfer for a given fluorophore pair (45 Å for terbiumfluorescein), tD is the measured lifetime of the donor when bound to the protein and
without acceptor fluorophore present, and tDA is the lifetime of the donor fluorophore
when bound to the protein and transferring energy to the acceptor fluorophore, which
we have measured here as the lifetime of the sensitized emission of the acceptor. For
LRET experiments, the number of biological replicates for apo, glutamate, apo-CsCl,
and glutamate–CsCl was, respectively, n = 3. Final lifetime values for given conditions
were obtained by averaging the Background-subtracted lifetime values per day.

smFRET sample preparation
HEKUX\T cells were transiently transfected according to JetPrime protocol at
WV µg per WV cm plate. One day post-transfection, cells from two WV-cm dishes were
harvested and washed with extracellular buffer and labeled for W h at room
temperature with [VV nM of donor fluorophore Alexa ddd maleimide (ThermoFisher)
and [VV nM of acceptor fluorophore Alexa ][f maleimide (ThermoFisher) in \ mL
extracellular buffer. This concentration of fluorophore was determined to be optimal
for single donor and single acceptor labeling. After washing, labeled cells were then
solubilized for W h at [ °C in solubilization buffer consisting of phosphate-buffered
saline, W% lauryl maltose neopentyl glycol (MNG-\) (Anatrace), U mM cholesteryl
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hydrogen succinate (MP Biomedicals), and ¼ protease inhibitor tablet (Pierce).
Unsolubilized debris were then spun down for W h at WVV,VVV × g at [°C, and the
supernatant used as the smFRET sample. Samples were then diluted W:U in cold SB
before application.

smFRET flow chamber preparation
Coverslips (UU × UU mm No. W) were washed with Liqui-Nox phosphate-free
detergent (Alconox Inc.) and [.\% NH[OH and [.\% HUOU. Coverslips were then
plasma cleaned using a Harrick Plasma PDC-\UG Plasma Cleaner and then
aminosilanized through Vectabond treatment (Vector Laboratories). A circular area
on the slide was then isolated using Silicone templates (Grace bio-Labs) and treated
with a PEG solution containing d kDa biotin-terminated PEG (U.d% w/w in molecular
biology grade (MB) water, NOF Corp.), and d kDa mPEG succinimidyl carbonate (Ud%
w/w in MB water, Laysan Bio Inc.) in V.WM sodium bicarbonate (Sigma-Aldrich)
overnight in a dark and moist environment. On the day of the experiment, the
coverslips were washed with PBS, treated with short chain \\\ Da NHS-ester PEG
(Thermo Scientific) and incubated for U–\ h. Slides were then washed and dried with
NU gas. A chamber was then constructed over the treated circular area by applying
hybriwell chambers (Grace bio-Labs) then dual silicon press-fit tubing connectors
(Grace bio-Labs).
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smFRET protein preparation and attachment to coverslip
Streptavidin was applied to the chamber by flowing \U µl of a buffer solution
containing phosphate-buffered saline (PBS), W mM DDM (n-dodecyl-β-D-maltoside),
V.U mM CHS (cholesteryl hydrogen succinate), and V.U mg/mL Streptavidin through
the flow chamber and incubating for WV min. WVnM of biotinylated goat Anti-Rabbit
IgG (H+L) secondary antibody (Jackson Immunoresearch Laboratories, Inc., cat. no.
WWW-V]d-VV\) was then flowed into the chamber, incubated for UV–\V min, then
washed with PBS. Next, WV nM of anti-GluKU (C-terminal epitope) mouse monoclonal
primary antibody (Abcam, cat. no. abWd\Vf) was flowed in, incubated for UV–\V min,
and washed with PBS. This antibody was chosen as it is far from the extracellular sites
being studied. Detergent solubilized HEKUX\T cell membranes containing GluKU
receptors were then bound to a glass slide using the in situ immuno-precipitation
(SiMPull(UW\)) method for FRET data acquisition. ]V μL of the sample was applied
twice through the chamber followed by a UV–\V min incubation before flushing the
chamber with ]V µl oxygen scavenging solution buffer system (ROXS) buffer twice.
ROXS buffer used consisted of W mM methyl viologen, W mM ascorbic acid, V.VW% w/w
pyranose oxidase, V.VVW% w/v catalase, \.\% w/w glucose (all from Sigma-Aldrich), W
mM DDM (Chem-Impex), and V.U mM CHS (MP Biomedicals, LLC) in PBS, pH f.[. W
mM glutamate was added and/or WdV mM CsCl was used to replace NaCl in the ROXS
to achieve the experimental conditions and WmM UBP\WV was included for antagonistbound experiments.

126

smFRET data acquisition
For Single molecule FRET measurements were acquired using a custom-built
PicoQuant MicroTime UVV Fluorescence Lifetime Microscope. smFRET data
acquisitions were conducted using pulsed interleaved excitation at YV MHz. Both d\U
nm (LDH-D-TA-d\V; Picoquant) and ]\f nm (LDH-D-C-][V; Picoquant) lasers were
simultaneously used to characterize the fluorescent behavior of both fluorophores and
the efficiency of energy transfer between molecules potentially showing FRET. The
sample slide was immobilized on a scanning x-y-z piezo stage (P-f\\.UCD; Physik
Instrumente) while being excited and observed through a WVVx oil immersed lens
(WVV× W.[ NA; Olympus). The photons emitted from the sample post-excitation were
collected back through the objective, separated through a dual band dichroic beam
splitter (Ztd\U/][Vrpc-UF\; AHF/Chroma) and sent to two SPAD photodiodes (SPCM
CD\dW]H; Excelitas technologies) preceded by excitation filters. A ddV nm (FFVWdYU/][;AHF/Semrock) and ]dV nm (UXH]XV/fV;AHF) emission filter were used for
the donor and acceptor channels, respectively. All acquisitions were performed in the
presence of a photo-stabilizer and oxygen scavenging solution buffer system (ROXS).

smFRET molecules selection and analysis
Since the kainate receptors studied here are homomeric, there is a distribution
of various donor/acceptor combinations. To exclude signal from those channels
having multiple donors or multiple acceptors, the fluorescence intensity of single
channels and the step-wise photobleaching was studied. Multiple donors or acceptors
have multiple photobleaching steps and these traces were not used. The number of
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photobleaching steps per molecule in the U]] and [fX data sets exhibited the
following distribution: WV% showed four steps, dV% showed three steps, \d% showed
two steps, and d% showed one step. The FRETing regions of the smFRET traces
obtained for all constructs were on average W to \ seconds in length. Only the traces
with a clear single photobleaching step in both donor and acceptor channels were
included in the analysis. This molecule hence reports on a single distance between
single donor and single acceptor. Such a strategy has been used successfully by us as
well as several other laboratories (W\[, WdY, UW[, UWd).

The fluorescence intensity of the donor and acceptor (upon excitation of
donor) were used to calculate FRET efficiencies as described in these references (W\[,
Wdd-WdY, W]V, WfV, WfY). The photon counts produced per donor and acceptor excitation
were acquired at W ms resolution, binned to d ms, and denoised with wavelet
decomposition, and the calculated efficiencies were then plotted as separate
histograms showing the occurrence of photons at their observed FRET efficiencies.
Each count in the histogram represents one d ms bin, with the cumulative of all such
counts from all the molecules normalized.

The number of states that best describes the distribution of FRET efficiencies
found in the obtained FRET data was then determined using Step Transition and State
Identification (STaSI) analysis (WYV) and hidden Markov modeling using HAMMY
(WfX) and fit to Gaussian distributions.
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While we have provided distances based on the smFRET intensities it should
be noted the distances are between the fluorophores and hence the size and length of
the fluorescent probes brings additional errors in the estimation of distances. Thus we
focus on the change in distances and heterogeneity between the different states being
studied. This is a reasonable assumption as the size of the probes is not expected to
change between the states being studied. Furthermore, the heterogeneity and
transitions across states are evident in the single molecule traces where a given donoracceptor pair is being probed.

Free energy calculations
The free energy of the most populated state identified by STaSI analysis was set to V
kBT. The percent occupancies as determined by STaSI were then used to calculate the
equilibrium constant Keq between states, and the free energy of every state relative to
the most populated state was determined using the equation:

∆Gb =−kBT lnKeq

The transition probabilities between each pair of states, given our d ms bin time, was
used to determine the reaction rate for each transition, and the heights of the energy
of activation barriers were calculated assuming a first-order reaction rate and using
the Arrhenius equation:

k = Ae−Ea /kBT
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Where k is the rate constant, the concentration of the starting state was taken as the
STaSI-derived fractional occupancy of that state, and the value of the pre-exponential
was chosen to be WV ms−W. Forward and reverse energies of activation were averaged in
the final figure.

Statistics
Data were analyzed using Origin (OriginLab Corp.), MATLAB (MathWorks),
and Excel (MicrosoftCorp.). For smFRET experiments, the numbers of molecules that
passed cross- and anti-correlation checks for A[fXC-apo, A[fXC-glutamate, A[fXCapo-CsCl, A[fXC-glutamate–CsCl, SU]]C-apo, SU]]C-glu, Dff]K-glutamate, Dff]Kglutamate- CsCl, SU]]C-UBP\WV and A[fXC-UBP\WV were, respectively, n = df, ]], dd,
dU, [f, dV, [f, dd, UX and UY.
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Heteromeric studies
Parts of this section are based upon research originally published in Biochimica
et Biophysica Acta- Biomembranes. Litwin, D. B., N. Paudyal, E. Carrillo, V. Berka, and
V. Jayaraman. The structural arrangement and dynamics of the heteromeric
GluKU/GluKd kainate receptor as determined by smFRET. Biochimica et Biophysica
Acta- Biomembranes. UVWX; DOI: WV.WVW]/j.bbamem.UVWX.Vd.VU\ © Elsevier B.V.

Homology modeling
\ homology structures were made for heteromeric GluKU/GluKd. U models were built
based on homomeric GluKU one in antagonist bound form (PDB dKUF) and other in
agonist-bound form exhibiting desensitized state (PDB:dKUH). These models were
built using SWISS MODEL server accessible via EXPASy web server (UW]). The third
model was built based on the antagonist bound AMPA structure (PDB:\KGU). This
model was built using MODELLER software (UWf) . Antagonist bound structures
represent closed state similar to apo structure and hence are used for the analysis of
apo state.

Generation of FRET constructs
The R. norvegicus GluKU construct used previously in cryo-EM (U], UX) and
smFRET (UVV) experiments was used and retained the native glutamine at site dXV.
The GluKU coding sequence was PCR amplified and inserted into pcDNA\.W. The
background GluKU FRET construct was created by mutating the non-disulfide bonded
cysteines CXW, CWXX and C[\U to serines. From this background five constructs were
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created. One with SU]] mutated to cysteine, one with A[fX mutated to cysteine, one
with SdU\ mutated to cysteine, one with both A[fXC and Dff]K mutations, and one
with both SdU\C and Dff]K mutations.
The R. Norvegicus construct containing GluKd was kindly provided by Geoffrey
Swanson, PhD. The GluKd coding sequence was PCR amplified and inserted into
pcDNA\.W. The background GluKd FRET construct was created by mutating the
cysteines CW[, CYY and CUfV to serines. From this background five constructs were
created. One with SU]d mutated to cysteine, one with A[fW mutated to cysteine, one
with SdWd, one with both A[fWC and Dff]K mutations and one with both SdWdC and
Dff]K mutations.

Electrophysiology
HEK 293T cells at 30% confluency were transfected using lipofectamine 2000
(Invitrogen) with GluK2 and GluK5, co-transfected with GFP at a microgram ratio of
1:4:0.5. Whole cell patch clamp recordings were performed 24-48 h after transfection,
using firepolished borosilicate glass (Sutter instruments) pipettes with 3-5 mΩ
resistance, filled with internal solution: 110 mM CsF, 30 mM CsCl, 4 mM NaCl, 0.5 mM
CaCl2, 10 mM HEPES, and 5 mM EGTA (adjusted to pH 7.4 with CsOH). The external
solutions contained 150 mM NaCl, 2.8 mM KCl, 1 mM CaCl2 and 10 mM HEPES
(adjusted to pH 7.4 with NaOH). The glutamate (10 mM) was applied to cells using a
stepper motor system (SF-77B; Warner Instruments) with Triple barrel tubing.
Recordings were performed using an Axopatch 200B amplifier (Molecular Devices) at
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−60 mV hold potential, acquired at 10 kHz using pCLAMP10 software (Molecular
Devices) and filtered online at 5 kHz.

smFRET sample preparation
HEK293T cells grown on 10cm plates were checked for approximately 50% confluency.
The cells were then transfected with 20 µg DNA per 10 cm plate following JetPrime
protocol. DMEM media was changed after four hours of transfection and was left for
overnight expression. Next day, cells were collected from two transfected 10 cm plates
and were washed with 3mL of extracellular buffer (ECB). The sample was then
wrapped in foil and was labeled with 400 nM of Alexa 555 maleimide (ThermoFisher),
a donor fluorophore and 400 nM of Alexa 647 maleimide (ThermoFisher), an acceptor
fluorophore, in 3mL ECB at room temperature for 1hr. The labelled cells were washed
with 3mL ECB and were resuspended in 2mL of solubilization buffer by nutating at
4°C for one hour. Solubilization buffer consists of phosphate-buffered saline, 1% lauryl
maltose neopentyl glycol (Anatrace), 2 mM cholesteryl hydrogen succinate (MP
Biomedicals), and ¼ protease inhibitor tablet (Pierce). The nutated sample was then
transferred to an ultracentrifuge tube and was spun for one hour at 44000 rpm at 4°C
using a TLA 100.3 rotor for filtering unsolubilized debris. Supernatant thus collected
were used as smFRET samples and were kept on ice until they were used.

smFRET slide preparation

Microscope glass slides (20 × 20 mm) were cleaned in a solution of Liquinox
phosphate-free detergent (Alconox Inc.) via bath sonication followed by washing with
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solution consisting 4.3% NH4OH and 4.3% H2O2. Slides were then washed with purified
water, dried with nitrogen gas and placed in metal slide holder. Plasma cleaning of the
slides was done using Harrick Plasma PDC-32G Plasma Cleaner and then the slides were
treated with Vectabond (Vector Laboratories, CA) for aminosilanization and stored under
vacuum. Clean silicone templates (Grace bio-Labs) which were bath sonicated, and
methanol treated were dried using nitrogen flow and were placed at the center of the
slides. The slides were then treated with 50µl of PEG solution (0.25% w/w biotinylated
PEG, 25% w/w mPEG-succinimidyl carbonate, 0.1M NaHCO3) and incubated in a dark
moist environment overnight. On the day of the experiment, after cleaning the slides with
purified water and dried with nitrogen, slides were applied with short chain PEG solution
(25mM short-chain 333 Da MS(PEG)4 Methyl-PEG-NHS-Ester Reagent, 0.1 M
NaHCO3) and were incubated at room temperature for two to three hours. Then, the
slides were washed with water, dried with nitrogen and silicone templates were removed
followed by applying Hybridwell chambers and press-fit tubing connectors (Grace bioLabs). 36 µl of streptavidin solution (0.2 mg/mL streptavidin, 1×smFRET imaging buffer
(1mM DDM (n-dodecyl-β-D-maltoside), 0.2mM CHS (cholesteryl hydrogen succinate),
1×PBS) was applied to the chamber, incubated for 10 minutes and was washed with
1×PBS. The smFRET sample was then applied to the slide and incubated at 4°C for 20
minutes followed by washing of slides two times with 60 µl ROXS (reactive oxygen
species) scavenging solution (3.3% w/w glucose, 0.1mg/mL pyranose oxidase, 0.01
mg.mL catalase, 1mM ascorbic acid, 1mM methyl viologen and/or 1mM glutamate)
(Sigma-Aldrich). Finally, the slides were ready for imaging.
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smFRET data collection
A PicoQuant MicroTime UVV Fluorescence Lifetime Microscope, a kind of
confocal microscope, was used for acquiring the smFRET data with pulsed interleaved
excitation (PIE) set at YV MHz. The fluorophores were excited by using d\U nm (LDHD-TA-d\V; Picoquant) and ]\f nm (LDH-D-C-][V; Picoquant) lasers simultaneously.
The sample slide positioned on a scanning x-y-z piezo stage (P-f\\.UCD; Physik
Instrumente) was observed through an oil immersed WVVX objective lens (WVV× W.[ NA;
Olympus). Two SPAD photodiodes (SPCM CD\dW]H; Excelitas technologies) collected
photons emitted from the sample passing through objective to the emission filters ddV
nm (FFVW-dYU/][; AHF/Semrock) and ]dV nm (UXH]XV/fV;AHF) to the photodiodes.

smFRET data analysis
Molecules exhibiting a single donor and single acceptor photobleaching step
with anticorrelation upon acceptor bleaching were used for analysis. Intensities for
donor and acceptor were then used for the calculation of FRET efficiencies. MATLAB
(MathWorks) was used for denoising donor and acceptor traces using wavelet based
denoising. Origin (OriginLab Corp) was used for obtaining smFRET histograms which
included overlaid denoised and observed data, and gaussian curve fitting to represent
FRET states. The total number of molecules used for the analysis of each conditions
are, UY molecules for GluKU*-U]] - GluKU*-U]], U]-UY molecules for GluKU*-[fX GluKd*-[fW, and Uf-\W molecules for GluKU*-dU\ - GluKU*-dU\ and GluKd*-dWd GluKd*-dWd.
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KRAS smFRET studies
Parts of this section are based upon research originally published in Biophysical
Journal. Prakash, P., D.B. Litwin, H. Liang, J. Hancock, V. Jayaraman and A. Gorfe.
Dynamics of membrane-bound GWUV-KRAS from simulations and single-molecule
FRET in native nanodiscs. Biophysical Journal. UVWX; WW](U): WfX-WY\ © Biophysical
Society.

Extraction of G12V-KRAS in native NDs
To measure FRET distance between fluorophore-labeled residues 132 and 183 (ζ∗), we
generated a hemagglutinin (HA)-His-tagged G12V-KRAS with D132C/T183C/C118S
mutations (G12V-KRAS∗). In this construct, D132C and T183C provide surface-exposed
cysteines for site-specific fluorescent labeling, whereas C118S eliminates the only
surface cysteine to avoid nonspecific labeling. The C118S mutation does not affect
structure or function (218). Similarly, we do not expect major structural or functional
effects from mutations at the surface residues D132 or T183. The His tag was added to
aid surface immobilization, and HA to enhance expression of the Cys mutant KRAS.
The construct was expressed in baby hamster kidney (BHK), cells grown to
confluency, and styrene-maleic acid (SMA) extracted in NDs, as follows. Intact cells
suspended in phosphate-buffered saline (PBS) containing 20 μg/mL
deoxyribonuclease and 0.5 mM phenylmethylsulfonyl fluoride were treated with 2%
SMA for 1 h at room temperature under rotation. After ultracentrifugation at
100,000 × g for 1 h at 4°C, the supernatant containing ND-bound G12V-KRAS∗ was
collected and quantified using Western blotting. On the day of analysis, the
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supernatant containing ND-G12V-KRAS∗ was incubated with a 1:4 molar ratio of Alexa
Fluor 555 (donor) and Alexa Fluor 647 (acceptor) maleimide (Invitrogen, Carlsbad,
CA) for 1 h at room temperature under rotation. Excess dye was removed using a PD10 desalting column (GE Healthcare Life Sciences, Waukesha, WI).

FRET data acquisition and analysis
The labeled protein was diluted 5× and immobilized on a glass surface for smFRET
measurements. A custom-built PicoQuant MicroTime 200 Fluorescence Lifetime
Microscope was used for smFRET measurements at 80 MHz using pulsed interleaved
excitation. The 532 nm (LDH-D-TA-530; PicoQuant, Berlin, Germany) and 637 nm
(LDH-D-C-640; PicoQuant) lasers were used to characterize the efficiency of energy
transfer between molecules potentially showing FRET. The sample was excited and
observed through a 100× oil immersed lens (100× 1.4 NA; Olympus, Tokyo, Japan)
while immobilized on a scanning x-y-z piezo stage (P-733.2CD; Physik Instrumente,
Auburn, MA). The photons emitted from the sample post excitation were separated
through a dual-band dichroic beam splitter (Zt532/640rpc-UF3; adaptive high
frequency [AHF]/Chroma, Los Angeles, CA) and sent to two single-photon avalanche
photodiodes (SPCM CD3516H; Excelitas Technologies, Fremont, CA). The 550 nm
(FF01-582/64; AHF/Semrock, Rochester, NY) and 650 nm (2XH690/70; AHF) emission
filters were used for the donor and acceptor channels, respectively. ROXS was used
during all data acquisitions. The photon counts were acquired at 1-ms resolution,
binned to 10 ms, denoised with wavelet decomposition, and plotted as separate
histograms showing the occurrence of photons FRETing at their observed efficiencies.
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Step transition and state identification (STaSI) analysis was then used to determine
the number of states that best describes the distribution of FRET efficiencies found in
the obtained FRET data. The free energy (in terms of kBT) associated with each STaSIidentified state (ΔG) was calculated by setting the most populated state to 0 kBT and
using the frequency of state occurrences relative to the most populated state as .
The energy barriers between states were assumed to be of first-order kinetics and
calculated using the Arrhenius equation. The concentration of the starting state was
taken as the STaSI-derived fractional occupancy of that state. Forward and reverse
energies of activation were averaged. Data were analyzed using Origin (OriginLab,
Northampton, MA), MATLAB (The MathWorks, Natick, MA), and Excel (Microsoft,
Tulsa, OK). For smFRET experiments, after filtering out the molecules that failed the
anticorrelation check, the number of particles was n = 13.
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LRET and cryo-EM into Neto2 modulation

LRET studies of Neto2
LRET experiments were prepared and analyzed as previously discussed.

Generation of baculovirus constructs
The open reading frame containing GluK2 and eGFP used previously in cryo-EM
experiments (26) was cloned into a pFastBac1 vector using the Gibson Assembly
method. The open reading frame for Neto2 was cloned into a pFastBac1 vector using
the Gibson Assembly method.

P1 baculovirus stock
Approximately 8x105 SF9 cells were plated into a six well plate and allowed to adhere
for 20 min. media was aspirated and replaced with plating media (1.5 ml Grace’s insect
medium- 10% FBS with 8.5 ml Grace’s insect medium) 8 µl of Cellfectin reagent was
then diluted into 100 µl Grace’s media unsupplemented. 2 µl of bacmid DNA was
diluted into plating media, then mixed by lightly flicking the tube. The Cellfectin and
DNA solutions were then mixed and incubated at room temperature for 30 minutes.
The mixture was added dropwise onto the cells, mixed and incubated at 27°C for 5
hours. After 5 hours, the media was aspirated and replaced with Graves’s medium +
10% FBS. After observing 70% of cells lysing, the supernatant was removed,
centrifuged at 500 x g for 5 minutes and the remaining supernatant was kept as the P1
stock. Viral titers were determined using 1:10 dilutions and plaque quantitation. P2
139

viral stocks were generated by applying the P1 stock at an MOI of 0.1 to SF9 cells
seeded at 2x106 cells per well, incubating 48 hours, and collecting the supernatant.
Again, viral titers were determined using 1:10 dilutions and plaque quantitation.

Expression
500 ml SF9 suspension cultures were prepared at 1 x 106 cells per ml. P2 viral stock was
added at an MOI of 1 per construct and incubated at 27°C for 48 hours. The media was
collected, centrifuged at 1,000 x g for 15 minutes and the cell pellet was kept for
analysis. Cell viability was quantitated using trypan blue.

Purification for cryo-EM
Approximately 300 x 106 transfected SF9 cells were resuspended in 5 ml PBS. The cells
were centrifuged at 1,000 x g for 15 minute and the supernatant was removed. The cells
were resuspended in lysis buffer (5 mM MgCl, 2.5 mM KCl, 1.5 mM KH2PO4, 150 mM
NaCl, 8 mM Na2HPO4, 0.1 mM CaCl2, 1 µg/ml DNase, pH 7.4), then lysed using a parr
bomb pressurized to 750 psi for 5 min. cell debris was cleared by centrifuging at 500 x
g for 10 minutes, then membrane fractions were collected by centrifuging at 100,000 x
g for 30 minutes. The supernatant was aspirated, and the cell pellet transferred to a
Dounce homogenizer. The pellet was then homogenized into 7 ml lysis buffer (no
DNase with fresh protease inhibitors). The homogenized membrane fraction was then
mixed with 7 ml SMA buffer (5 mM MgCl, 2.5 mM KCl, 1.5 mM KH2PO4, 150 mM
NaCl, 8 mM Na2HPO4, 0.1 mM CaCl2, 3.3 % SMA, pH 7.4) and incubated overnight at
room temperature with gentle shaking. The sample was then spun at 100,000 x g for 1
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hour. The supernatant was then applied to Ni-NTA resin in batch format and gently
rocked at 4°C for 4 hours. The resin was allowed to settle at 1 x g for 20 minutes. The
resin was then washed three times in 10 ml PBS-Arg buffer and followed by elution in
2 ml PBS-Arg buffer containing 400 mM imidazole. The eluate was fractionated using
a superdex 6 10/200 gel filtration column (GE) and the fractions containing the
complex were combined and concentrated using spin columns (Amicon).

Cryo-EM imaging
The purified KAR-Neto2 complex at approximately 0.3 mg/ml protein were plunge
frozen on Quantifoil holey grids (Quantifoil Micro Tools GmbH) The grids were
previously covered with a thin continuous carbon film and glow-discharged for 5
seconds. Vitrification was performed at 80–90% humidity, 22°C using a Vitrobot (FEI).
The grids were imaged using a Technai G2 Polara electron microscope (FEI) operated
at 200 kV using a K2 Summit direct electron detector camera (Gatan).
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